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High consumption of dairy products, particularly non-fat dairy, is 
associated with reduced risk of high blood pressure and vascular dysfunction.  
Currently, it is not known if the solitary addition of conventional non-fat dairy 
products to the normal routine diet is capable of reducing blood pressure or 
improving vascular function.  Accordingly, the primary aims of the present study 
were to determine if the solitary addition of conventional non-fat dairy products to 
the normal routine diet would reduce blood pressure and improve vascular 
function in middle-aged and older adults with elevated blood pressure.   
Using a randomized, crossover intervention study design, forty-nine adults 
with elevated blood pressure underwent a High Dairy condition (+4 servings/day 
of conventional non-fat dairy products) and isocaloric No Dairy condition (+4 
servings/day fruit products) in which all dairy products were removed.  Both 
 vii 
dietary conditions lasted 4 weeks with a 2-week washout before crossing over 
into the alternate condition.  In Study 1, the High Dairy condition produced 
reductions in brachial systolic blood pressure and pulse pressure.  The 
hypotensive effects were observed within three weeks after the initiation of 
dietary intervention and in both casual seated and ambulatory (24-hour) 
measurements.  On the contrary, pulse pressure was increased after removal of 
all dairy products in the No Dairy condition compared to baseline and after in the 
High Dairy condition.  There were no changes in diastolic blood pressure after 
either dietary condition.   
In Study 2, the High Dairy condition produced reductions in carotid systolic 
blood pressure, pulse pressure, and carotid-femoral pulse wave velocity with a 
concomitant increase in brachial flow-mediated dilation and cardiovagal 
baroreflex sensitivity.  Brachial flow-mediated dilation decreased and carotid 
pulse pressure increased after removal of all dairy products in the No Dairy 
condition.  Furthermore, ∆ carotid systolic blood pressure and carotid-femoral 
pulse wave velocity were highly related.  Taken together, we concluded that the 
solitary manipulation of conventional dairy products, particularly non-fat dairy, in 
the normal routine diet would modulate levels of blood pressure and vascular 
function in middle-aged and older adults with pre-hypertension and hypertension.   
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Chapter 1: General Introduction 
In most of the developed world, diseases of the cardiovascular system are 
responsible for more annual deaths than any other cause [1].  The progression of 
cardiovascular disease (CVD) is primarily an age-related phenomenon.  So, for 
most individuals living in industrialized societies, with advancing age brings 
increased risk of CVD and events [2, 3].  It is well documented that elevated 
blood pressure (BP) (systolic BP ≥ 120 mmHg and/or diastolic BP ≥ 80 mmHg) is 
a major contributor to the progression of CVD; approximately 90% of those with 
CVD are also hypertensive (systolic BP ≥140 mmHg and/or diastolic BP ≥ 90 
mmHg or currently being prescribed BP-lowering medications) [4].  Increases in 
systolic BP are also closely associated with aging, with the greatest increases 
occurring in prehypertensive and hypertensive individuals [5-7].  A major 
contributor to age-related increases in BP with age is change in vascular stiffness 
or compliance of central elastic arteries (e.g., aorta and carotid arteries) [8].  
Increases in central arterial stiffness are related to aging [9] and increased BP 
[10] and are also predictive of cardiovascular events [11]. Thus, vascular 
dysfunction, namely central arterial stiffness, is an underlying risk factor 
associated with elevated BP and the aging process that when modified, greatly 
reduces the risk of CVD.  Therefore, a primary focus of healthy aging is to 
promote a lifestyle that maintains normal BP and preserves vascular function.   
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The first line approach in clinical treatment of elevated BP is the adoption 
of healthy lifestyle modifications [12, 13].  Consuming a diet that is high in fruits, 
vegetables, and low- and non-fat dairy products, but low in total fat, saturated fat, 
and sodium is considered a healthy lifestyle modification and has been 
consistently shown to reduce BP [14-19].  Although the adoption of this diet 
reduces BP and overall risk of CVD, some dietary components may be more 
effective in lowering BP than others.  One of the most cited and well known 
studies to date is the Dietary Approaches to Stop Hypertension (DASH) [20], in 
which over 500 subjects completed one of three, 8-week long dietary 
interventions: 1) typical western diet, 2) diet high in fruits and vegetables, and 3) 
diet high in fruits and vegetables with additional portions of low-fat dairy products 
(currently termed DASH eating plan).  Compared to the typical western diet, both 
diets that increased daily servings of fruits and vegetables reduced systolic and 
diastolic BP, with the greatest reductions in BP occurring in the DASH group.  
Furthermore, reductions in BP observed in the DASH group were also 
significantly greater than those observed in the fruits and vegetables diet that had 
no added dairy products.  These findings demonstrate the ability of low- and non-
fat dairy products to reduce BP and have been supported by other studies with 
similar DASH intervention [14-19].  Most of the studies demonstrating a 
hypotensive effect with increased daily amounts of low- and non-fat dairy 
products incorporated other dietary or lifestyle changes (e.g., weight loss, 
increased physical activity).  Less is known about whether the addition of non-fat 
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dairy products to the normal routine diet is able to reduce BP without other 
concomitant lifestyle or dietary changes.  While it has been shown that 
individuals who consume greater daily portions of low-fat dairy products have 
lower central arterial stiffness [21], no study has investigated the effects on 
vascular function in response to these lifestyle modifications.  Therefore purpose 
of this study was to determine whether a dietary intervention that increases daily 
consumption of conventional non-fat dairy products would exert hypotensive 
effects and/or improve vascular function.   
This study employed a randomized crossover design consisting of two 
dietary conditions: 1) High Dairy condition (+4 servings/day non-fat dairy 
products) and 2) isocaloric No Dairy condition (+4 servings/day fruit products) 
with all dairy products removed from the diet.  Using this design we determined 
the hypotensive effects of non-fat dairy products, as well as changes in vascular 
function related to these reductions in BP.  A total of 53 middle-aged and older 
adults (35-80 years old) with elevated systolic BP (≥120-159 mmHg) were 
recruited for this study.  All subjects were in prehypertension or stage-1 systolic 
hypertension classifications, as classified by the Seventh Report of the Joint 
National Committee on Prevention, Detection, Evaluation, and Treatment of High 
Blood Pressure (JNC) [13].  Dietary conditions were in randomized order and 
four weeks in length with a washout period of at least two weeks before crossing 
over into the alternate dietary condition.  Measurement of casual seated BP, 
ambulatory BP, central arterial stiffness, and endothelial vasodilatory function 
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were assessed prior to and at the end of each dietary condition.  It was 
hypothesized that in the High Dairy condition, BP would be reduced and vascular 
function improved, compared to the No Dairy condition. 
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Research Purpose and Hypotheses 
Study #1: The first study focused on the hypotensive effects of conventional 
non-fat dairy products in casual resting and ambulatory conditions.  This study 
used a crossover design to determine the effects of a dietary condition that is 
high in non-fat dairy products (+4 servings non-fat dairy product; High Dairy 
condition), compared to an isocaloric No Dairy condition (+4 servings fruit 
products; No Dairy condition) with all dairy products removed from the diet.  The 
specific hypotheses were as follows: 
1. The addition of 4 servings/day of non-fat dairy products in the High 
Dairy condition would result in lower casual seated, supine and 
ambulatory BP values, compared with baseline. 
2. The removal of all dairy products in the No Dairy condition would result 
in higher casual seated, supine, and ambulatory BP values, compared 
with baseline, as well as after the High Dairy condition. 
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Study #2: The second study focused on changes in central BP and vascular 
function (e.g., central arterial stiffness, endothelial vasodilatory function, etc.) that 
may be related to reductions in BP in the High Dairy condition, compared with No 
Dairy condition observed in study #1.  The specific hypotheses are as follows: 
1. The addition of non-fat dairy products in the High Dairy condition would 
result in reduced central BP and improved vascular function, compared 
with baseline. 
2. The removal of all dairy products in the No Dairy condition would result 
in higher central BP and attenuated vascular function, compared with 
baseline, as well as after the High Dairy condition. 
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Chapter 2: Study 1 - Hypotensive Effects of Solitary Addition of 
Conventional Non-Fat Dairy Products to the Routine Diet: A 
Randomized Controlled Trial 
 
Abstract 
High consumption of low- and non-fat dairy products is associated with reduced 
risk of high blood pressure.  We aimed to investigate if the solitary addition of 
non-fat dairy products to the normal routine diet was capable of lowering blood 
pressure in middle-aged and older adults with elevated blood pressure.  Using a 
randomized, crossover intervention study design, forty-nine adults (56% women) 
with elevated blood pressure (53±2 yr, 135±1/80±1 mmHg) underwent a High 
Dairy condition (+4 servings/day of conventional non-fat dairy products) and 
isocaloric No Dairy condition (+4 servings/day fruit products) in which all dairy 
products were removed.  Both dietary conditions lasted 4 weeks with a 2-week 
washout before crossing over into the alternate condition.  The High Dairy 
condition produced reductions in systolic blood pressure (135±1 to 127±1 mmHg) 
and pulse pressure (54±1 to 48±1 mmHg) (both P<0.05).  The hypotensive 
effects were observed within 3 weeks after the initiation of dietary intervention 
and in both casual seated and ambulatory (24-hour) measurements (P<0.05).  
Pulse pressure was increased after removal of all dairy products in the No Dairy 
condition (54±1 to 56±1 mmHg, P<0.05).  There were no changes in diastolic 
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blood pressure after either dietary condition.  We concluded that the solitary 
manipulation of conventional dairy products in the normal routine diet would 
modulate levels of blood pressure in middle-aged and older adults with pre-
hypertension and hypertension.  This trial was registered at clinicaltrials.gov as 
NCT01577030. 
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Introduction 
Diseases of the cardiovascular system increase with advancing aging and 
are responsible for more annual deaths than any other causes [1].  One of the 
most important and predictive risk factors for CVD is elevated BP, particularly 
systolic BP and pulse pressure in middle-aged and older adults [22].  Although 
the risk of coronary heart disease is greater in hypertensive than normotensive 
adults at any age, the magnitude of risk elevation associated with hypertension is 
much greater in older adults as compared with young adults [2].  Clearly, from a 
societal standpoint, it is of paramount importance to reduce the incidence of 
systolic hypertension, particularly isolated hypertension, in middle-aged and older 
adults.   
In most individuals with elevated BP, the initial treatment approach is the 
adoption of healthy lifestyle modifications, including dietary changes [13].  The 
identification of dietary changes that lower BP comes from the observation that 
dietary calcium consumption, particularly from dairy products, was lower in 
individuals with hypertension [23].  In a follow-up study it was shown that dairy 
products, fruits, and vegetables were inversely related to BP [24].  These findings 
were used to describe the DASH diet, which is high in fruits, vegetables, and low- 
and non-fat dairy products, but low in total fat and sodium, and has been shown 
to lower BP in individuals with elevated BP [15, 20].  The DASH diet has become 
a mainstay of dietary modifications to reduce BP.  In one of the DASH diet 
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interventional studies [20], subjects completed one of 3 dietary interventions: 1) 
typical western diet, 2) diet high in fruits and vegetables, and 3) DASH diet.  
Subjects who consumed the DASH diet had the greatest reductions in BP.  
These reductions were even greater than in those who consumed the fruits and 
vegetables diet and were attributed to the addition of low- and non-fat dairy 
products in DASH diet.  It should, however, be noted that the hypotensive effects 
of the DASH diet cannot be ascribed to dairy products alone because other 
dietary changes (e.g., a reduction in total fat and saturated fat) were also 
incorporated.  Several other interventional studies have shown reductions in BP 
after consumption of a diet high in low- and non-fat dairy products [15-17, 25], 
although some studies have not shown this [26, 27].  However, most of these 
studies were controlled feeding studies or incorporated other dietary or lifestyle 
changes.  Currently, it is not known if the solitary addition of non-fat dairy 
products to the normal routine diet, without any other lifestyle or dietary changes, 
is capable of reducing BP.  We reasoned that such dietary approach would be 
more practical, adaptable, and generalizable for the secondary prevention of 
hypertension.   
Accordingly, the primary aim of the present study was to determine the 
effects of conventional non-fat dairy products added to the normal routine diet in 
middle-aged older adults with elevated BP.  Our working hypothesis is that the 
addition of non-fat dairy products would reduce BP.  Blood pressure was 
measured both in the casual resting state as well as in the ambulatory (24-hour) 
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condition.  In order to maximally differentiate the dietary dairy intake, all dairy 
products were removed from the routine diet in the control condition.   
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Methods 
Subjects.  A total of 49 adults (44% men and 56% women) with a mean 
age of 53±2 years were studied (Figure 2.1).  Subjects were recruited via 
advertisements on The University of Texas at Austin website, fliers posted on the 
campus and the surrounding community, and from our database of subjects who 
participated in previous studies in the laboratory.  Inclusion criteria were: 
elevated systolic BP in the seated position between 120 and 159 mmHg (pre-
hypertension or stage-1 systolic hypertension) with a diastolic BP of less than 
100 mmHg; no overt signs of chronic diseases on physical examination and 
medical history (e.g., diabetes, cancer); normal blood chemistry; ankle-brachial 
index ≤0.9; nonsmoker for previous 2 years; not lactose intolerant; dairy product 
consumption ≤3 servings/day, strenuous physical activity ≤3 days/week.  Five 
subjects were taking antihypertensive medications, and medication dosages and 
routines were maintained throughout the entire study.  Prior to entrance into the 
study, all subjects underwent a 2-week run-in period that included 3 screening 
visits to ensure that all subjects demonstrated stable BP within the appropriate 
range.  The University of Texas at Austin Institutional Review Board reviewed 
and approved the study.  All volunteers gave their written informed consent 
before participation. 
Experimental Design.  We used a controlled, randomized, crossover 
experimental design with two 4-week dietary conditions and a washout period of 
13 
at least 2 weeks separating dietary conditions.  The rationale for 4 weeks of 
dietary intervention was based on: a) recommendations from health care 
organizations regarding the use of non-pharmacological treatment strategies to 
improve cardiovascular risk factors; and b) the fact that BP changes very rapidly 
to intervention stimuli as early as 2-4 weeks; therefore, the 4 weeks would allow 
a sufficient period of time for the dietary product stimulus to produce the 
hypothesized effects.  Measurements were taken at the beginning and end of 
each dietary condition at the same time of day to eliminate any diurnal effects 
and after having abstained from food, alcohol, caffeine, and exercise for at least 
12 hours.  In premenopausal women, measurements were performed during the 
early follicular phase of the menstrual cycle.   
The 2 dietary conditions were: High Dairy condition and isocaloric No 
Dairy condition.  During the High Dairy condition, subjects added 4 daily servings 
of non-fat milk (HEB Grocery Company, San Antonio, TX), non-fat fruit juice 
sweetened yogurt (Cascade Fresh, Seattle, WA), and/or non-fat cheese Kraft 
Foods Group, Northfield, IL) on top of their baseline dietary dairy intake.  One 
serving of dairy was either 245 g of milk, 170 g of yogurt, or 57 g of cheese.  The 
research bionutritionist explained how much one serving of all dairy products was 
to each subject.  Milk was provided to subjects by the gallon or half-gallon with 
measuring cups.  Yogurt and cheese products were in single serve packaging.  
The subjects were free to consume the required servings at any time of day as a 
single dose or all at once.  During the No Dairy condition, all dairy products were 
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removed from the diet and 4 daily servings of fruit juice, applesauce, and/or fruit 
cups were added to the diet.  Additional servings of fruit products were provided 
to those with regular dairy consumption at baseline to counterbalance the 
calories lost due to removal of dairy products during the No Dairy condition.  Prior 
to the start of each dietary condition, subjects met with a research bionutritionist 
to have specific instructions about the dietary conditions explained to them.  After 
the dietary consultation, subjects received one-week worth of food products and 
returned weekly for additional food product refills.  Throughout the entire 
experimental protocol, subjects were instructed to maintain their normal lifestyle, 
aside from dietary changes prescribed by the laboratory research bionutritionist 
to reduce the overall caloric content when 4 servings of dairy or fruit products 
were added.  Research staff enrolled participants on the study, generated the 
random allocation to the treatment sequence (using a coin flip simple 
randomization), and implemented the allocation sequence.  Due to the nature of 
the experimental dietary conditions, it was not possible to blind subjects to what 
dietary condition they were currently in.  Additionally, there was no true placebo 
condition, as a lack of treatment provision was considered unethical.  The study 
was conducted from January 2012 to November 2013. 
Seated Brachial BP Measurements.  Seated brachial artery BP 
measurements were made with a semi-automated BP device (Omron HEM-
907XL, Omron Healthcare, Inc., Lake Forest, IL) in triplicate on the right arm after 
5 minutes in the upright seated position with the arm at heart level and under 
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quiet, comfortable, ambient (~24 ˚C) laboratory conditions [28].  In addition, in 
order to determine the time course of the BP changes with the dietary 
intervention, casual seated BP was measured during the weekly visits to the 
laboratory to refill food products.   
Ambulatory (24-hour) BP Measurements.  Ambulatory BP recordings were 
made over a 24-hour period of normal daily activity using a noninvasive 
ambulatory BP monitor (Model 90217, SpaceLabs Medical, Redmond, WA) [29].  
The ambulatory system was programmed to inflate automatically every 15 min 
from 6 AM to 11 PM and every 20 min between 11 PM and 6 AM.   
Blood Samples.  A blood sample was collected by venipuncture after an 
overnight fast.  Fasting whole blood concentrations of total cholesterol, HDL-
cholesterol, triglycerides, and glucose were determined enzymatically.  LDL-
cholesterol was estimated using the measured concentrations of total 
cholesterol, HDL-cholesterol, and triglycerides.  Whole blood glycated 
hemoglobin concentration (HbA1c) was measured using a commercially available 
HbA1c reagent kit (DCA Systems, Siemens Healthcare Diagnostics, Tarrytown, 
NY).   
Dietary Analyses.  Subjects were given detailed instructions on how to 
keep 3-day dietary records by the research bionutritionist.  During the weekly 
visits to the laboratory to refill food products, dietary records were collected 
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before and at the end of each dietary condition and analyzed using Nutritionist 
Pro software (Axxya Systems, Stafford, TX).  This software is based on the 
comprehensive food knowledge database with over 51,000 foods and 
ingredients.  Study compliance during each dietary condition was assessed by 
having each subject complete daily dietary surveys that indicated consumption of 
the food products provided, as well as any dairy products consumed as part of 
their normal diet.   
Statistical Analyses.  Power calculations were performed using nQuery 
Adviser computer software.  The alpha level used for power analyses was set at 
0.05.  Sample size calculations were based on the number of subjects needed to 
detect significant changes in primary dependent variables from baseline levels in 
response to lifestyle modifications [30-33].  With 49 subjects/group, we have 
greater than 80% power to detect the changes.  A 2-way and 3-way mixed model 
analysis of variance (ANOVA) with repeated measures was used to evaluate the 
effect of condition x time interaction by using SPSS software version 21 (IBM, 
Chicago, IL).  Where a significant condition x time interaction was found, paired-
samples t-tests with a Bonferroni correction were conducted to determine 
difference between specific time points.  Statistical significance was set at 
P<0.05 for all analyses.  Data are presented as mean ± SEM.  
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Results 
Subject compliance/adherence to the study protocol was 97 and 96% in 
the High Dairy and No Dairy conditions, respectively, based on the daily dietary 
survey.  Although no subjects blatantly consumed dairy products while in the No 
Dairy condition, a few subjects accidentally consumed dairy products (<1 
serving/wk) in the beginning of the No Dairy intervention Additionally, a few 
individuals did not consume all servings of study food products on a daily basis.  
When this occurred, we instructed subjects to consume the missing servings the 
following day.  Because the non-compliance here is fairly minor in nature, these 
subjects were included in the study sample.  The selected subject characteristics 
are presented in Table 2.1.  Body mass and metabolic profiles did not change 
with either dietary condition.  There were no sex (gender)-related differences in 
these responses to the dietary conditions or in any of the responses described, 
as assessed by 3-way mixed model ANOVA with repeated measures (sex x 
condition x time).  Accordingly, sex was dropped from the analyses.  
Elimination/addition of subjects with antihypertensive medications (n=5) did not 
affect the overall results.   
As shown in Table 2.2, there were no significant differences in total caloric 
intake between or within dietary conditions.  Dietary protein intake increased after 
the High Dairy condition, but decreased after the No Dairy condition (P<0.05).  In 
the High Dairy condition, total dairy intake increased significantly from 1.2±0.1 to 
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4.7±0.1 servings/day (P<0.05), with laboratory-provided non-fat dairy products 
accounting for 4.0±0.1 servings/day, with 2.0±0.1, 1.9±0.1, and 0.1±0.0 
servings/day coming from milk, yogurt, and cheese, respectively.  Conversely, in 
the No Dairy condition, total dairy intake decreased from 1.4±0.1 to 0.0±0.0 
servings/day (P<0.05).  The baseline dairy intake consisted of 0.4±0.1 and 
0.7±0.1 servings/day of non-fat and full-fat dairy products.  As expected, 
following the High Dairy condition, potassium, calcium, magnesium, and vitamin 
D intake increased (P<0.05); all of them, except for potassium, decreased after 
the No Dairy condition (P<0.05).  Most importantly, dietary consumption of 
potassium, calcium, magnesium, vitamin D, and dairy products were significantly 
different between conditions after the 4-week interventions (P<0.05 for all).   
 As depicted in Figure 2.2, systolic BP decreased significantly after the 
High Dairy condition (P<0.05).  No such changes were observed after the No 
Dairy condition.  There were no changes in diastolic BP after either dietary 
condition.  Pulse pressure was reduced by 6±1 (P<0.05) after the High Dairy 
condition and had an increase of 2±1 mmHg (P<0.05) after the No Dairy 
condition. 
Analyses of weekly BP measurements revealed that both systolic BP and 
pulse pressure were significantly decreased as early as the week 3 of the High 
Dairy condition (P<0.05) (Figure 2.3).  Additionally, these values at the weeks 3 
and 4 in the High Dairy condition were significantly different from those measured 
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during the same weeks in the No Dairy condition (P<0.05).  There were no 
significant changes in diastolic BP in either group. 
A general trend of changes in ambulatory BP was similar to those 
observed during casual seated BP measurement (Figure 2.4).  Ambulatory (24-
hour) systolic BP decreased significantly after the High Dairy condition, with most 
of the BP reduction coming from the daytime periods (P<0.05).  There were no 
changes in ambulatory diastolic BP after either dietary condition.  Ambulatory 
pulse pressure decreased (P<0.05) after the High Dairy condition during the 24-
hour and daytime periods. 
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Discussion 
The primary findings from the present randomized crossover study are as 
follows.  The addition of 4 daily servings of conventional non-fat dairy products to 
the normal routine diet decreased systolic BP and pulse pressure in middle-aged 
and older adults with elevated BP.  The reduction in casual seated BP was 
accompanied by the similar reduction in ambulatory (24-hour) BP due mainly to 
the decrease in daytime BP.  Conversely, when all dairy products were removed 
from the routine diet, pulse pressure increased significantly relative to baseline 
and after in the High Dairy condition.  These findings indicate that the solitary 
manipulation of non-fat dairy products can modulate BP in middle-aged and older 
adults with elevated BP.   
With advancing age, systolic BP increases and diastolic BP decreases 
resulting in a widening of pulse pressure [34].  Among middle-aged and older 
adults, pulse pressure is highly predictive of CVD risk, even more so than both 
systolic or diastolic BP [35].  In the present study, we observed significant 
reductions in systolic BP and pulse pressure following the High Dairy condition.  
The analyses of the time course indicate that the hypotensive effects of the non-
fat dairy products were significant as early as 3 weeks after the initiation of the 
High Dairy condition.  These results indicate that the solitary addition of 
conventional dairy products to the normal routine diet could produce significant 
21 
reductions in systolic BP and pulse pressure well within the time frame that 
lifestyle modifications including dietary changes are typically prescribed.   
 
The results of the present study are generally consistent with previous 
studies reporting that increased low- and non-fat dairy product consumption are 
associated with BP-lowering effects [15-17, 20, 25].  However, a dietary 
intervention study with a similar research design to the present study showed no 
hypotensive benefit after 61 overweight or obese individuals increased 
consumption of low-fat dairy products (+4 servings/day) for six months [26].  The 
conflicting results may be due to differences in dietary calcium intake.  Dietary 
calcium consumption has been shown to be lower in individuals with 
hypertension and inversely related to BP [23, 24].  There is evidence of calcium 
metabolism disturbances in individuals with hypertension [36], which may be due 
to low dietary calcium consumption [23, 24], as dietary calcium supplementation 
has been shown to reduce BP in hypertensive individuals [37].  When dairy 
product consumption is increased, dietary calcium consumption is increased 
accordingly.  In the present study, baseline calcium consumption was lower 
(~750 mg/day vs. ~1,100 mg/day) and the gradient in dietary calcium after the 
High Dairy condition was nearly 2-fold greater (~1,350 mg/day vs. ~700 mg/day) 
than the previous study [26]. Thus, changes in BP may have been due to 
differences in dietary calcium consumption after the dietary interventions.  
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Not only did we observe reductions in systolic BP and pulse pressure in 
the casual resting state, but we also observed significant reductions in the 
ambulatory state.  The magnitude of reductions in systolic BP and pulse pressure 
after the High Dairy condition was, however, less in the ambulatory 
measurements.  While BP treatment guidelines typically refer to BP values 
measured in the seated resting conditions, ambulatory BP measured in 24 hours 
is more representative of normal life and may be a better indicator of CVD risk 
than casual resting BP [38].  Thus, reductions in BP we observed in the 
ambulatory measurements after the High Dairy condition may have a greater 
prognostic benefits for middle-aged and older adults with elevated BP who seek 
to gain benefit from dairy products.   
A rather unanticipated finding of the present study is that pulse pressure 
increased significantly when the regular consumption of dairy products was 
removed from the routine diet.  Compared with the High Dairy condition that 4 
servings of non-fat dairy servings were added, a much lower quantity of dairy 
products were removed from the diet (1.4 servings/day) in the No Dairy condition.  
These results imply that the subjects studied in the present study were enjoying 
the hypotensive benefits from relatively modest consumption of dairy products in 
their routine diet.  One may argue that the increase in pulse pressure might have 
been due to the addition of fruit products provided in the No Dairy condition.  
However, fruit consumption is inversely related to BP and CVD [24, 39].  
Additionally, the national BP guidelines recommend increased dietary 
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consumption of fruit products, as well as low- and non-fat dairy products, to 
reduce BP [13].  We observed no changes in blood lipid profile, glucose, or 
HbA1c in the No Dairy condition that are consistent with the hypertensive effects.  
While fruit products provided were isocaloric to non-fat dairy provided in the 
alternate condition, they contained minimal protein and were higher in 
carbohydrate content.  The amount that dietary protein decreased after the No 
Dairy condition (10g) is the approximate amount contained in 1.4 servings of 
dairy products.  Dietary supplementation with milk proteins has been shown to 
reduce BP and local arterial stiffness [30]. A recent cross-sectional analysis 
indicates that total dairy food consumption is inversely related to pulse pressure 
and arterial stiffness [21].  Thus, it is plausible that the removal of protein 
provided from dairy products may have increased pulse pressure, as milk 
proteins have been shown to act as angiotensin converting enzyme (ACE) 
inhibitors [40].  In addition to changes in protein intake, there were reductions in 
magnesium, vitamin D, and calcium consumption after the No Dairy condition.  
These changes were expected with the removal of dairy products, as these 
nutrients are abundant in dairy products.  Meta-analyses have shown that dietary 
supplementation with magnesium, vitamin D, or calcium can result in small 
reductions (2-4 mmHg) in systolic BP [41, 42].  Thus, a decrease in dietary 
consumption of one or more of these nutrients in No Dairy condition may have 
increased pulse pressure.   
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For the prevention of hypertension and CVD, it is recommended that low- 
and non-fat dairy products be added to the diet [13].  This recommendation is 
presumably driven by a concern that high fat content in dairy products may 
increase the risk of obesity, diabetes, and CVD.  However, recent reviews have 
indicated no relation or even inverse relation of total dairy intake to metabolic and 
CVD risks [43-45].  Future studies are warranted to determine the effect of full-fat 
dairy products on BP.   
There are several strengths of the present study that can be emphasized.  
First, we kept each subject’s normal routine diet, as the baseline dietary 
conditions and only dairy and fruit consumption were experimentally 
manipulated.  We reason that such approach would be more generalizable to a 
greater number of populations who seek to conveniently adapt high dairy 
consumption in their normal diet.  Second, BP was measured in both the casual 
seated and ambulatory states, which allowed us to evaluate the effects of both 
dietary conditions in the clinical setting as well as in normal life.  There are 
several limitations as well.  We were unable to determine which non-fat dairy 
product was more effective in reducing BP.  Individuals in the study had the 
choice of non-fat yogurt, milk, and/or cheese, in addition to other dairy products 
consumed as part of their normal routine diet.  Additionally, we cannot determine 
which ingredients of dairy products (milk protein, calcium, potassium, milk 
peptide, etc.) were responsible for hypotensive effects of dairy products.   
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As in many other studies, the completion of the study brings more 
questions than we can answer.  What is the minimal and optimal dose of dietary 
dairy intake to reduce BP?  Are there any additive effects of dairy consumption to 
other lifestyle modifications (e.g., regular exercise)?  Could the effect of the 
solitary addition of dairy products to the normal routine diet be greater in ethnic 
minorities?  What is the physiological mechanism underlying the reduction in BP?  
There is no question that more studies are needed to fully evaluate the 
hypotensive effects of dairy products.   
 Lifestyle modifications, including dietary changes, are the first line 
approach for treating elevated BP.  The present findings indicate that simply 
adding 4 servings of conventional non-fat dairy products are effective in reducing 
both systolic BP and pulse pressure in middle-aged and older adults.  Unlike 
other lifestyle modifications, including regular exercise, that are difficult to 
achieve high compliance and adherence, dairy products can be easily 
incorporated into daily routine of older adults to gain hypotensive benefits. 
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Table 2.1.  Changes in Selected Subject Characteristics and Blood Chemistry 
  
No Dairy 
 
High Dairy 
 
Variables 
 
Before 
 
After 
 
Before 
 
After 
 
Height, cm 
 
170±2 
 
- 
 
170±2 
 
- 
 
Body mass, kg 
 
87.8±3 
 
87.7±3 
 
88.1±3 
 
88.3±3 
 
Body mass index, kg/m2 
 
30.4±1 
 
30.3±1 
 
30.5±1 
 
30.5±1 
 
Total cholesterol, mmol/l 
 
5.23±0.2 
 
5.10±0.2 
 
5.26±0.2 
 
5.23±0.2 
 
HDL cholesterol, mmol/l 
 
1.24±0.1 
 
1.11±0.1 
 
1.17±0.1 
 
1.14±0.1 
 
LDL cholesterol, mmol/l 
 
3.39±0.2 
 
3.39±0.1 
 
3.47±0.1 
 
3.42±0.1 
 
Triglycerides, mmol/l 
 
1.25±0.1 
 
1.30±0.1 
 
1.37±0.1 
 
1.48±0.1 
 
Blood Glucose, mmol/l 
 
5.27±0.1 
 
5.22±0.1 
 
5.33±0.1 
 
5.44±0.1 
 
HbA1c, % 
 
5.4±0.1 
 
5.4±0.1 
 
5.4±0.1 
 
5.4±0.1 
 
Values are mean ± SEM. 
All significant differences were preceded by a significant condition x time 
interaction. 
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Table 2.2.  Changes in Dietary Composition 
  
No Dairy 
 
High Dairy 
 
Variables 
 
Before 
 
After 
 
Before 
 
After 
 
Calories, kcal/day 
 
1,818±59 
 
1,842±45 
 
1,830±64 
 
1,880±50 
 
Fat, g/day 
 
71±4 
 
58±3 
 
69±3 
 
60±3 
 
Carbohydrate, g/day 
 
201±9 
 
251±7* 
 
203±10 
 
227±7*† 
 
Protein, g/day 
 
79±4 
 
69±3* 
 
82±3 
 
98±3*† 
 
Alcohol, g/day 
 
8±2 
 
6±2 
 
11±2 
 
6±2 
 
Sodium, mg/day 
 
2,923±190 
 
2,555±124 
 
2,753±141 
 
2,739±124 
 
Potassium, mg/day 
 
2,115±152 
 
2,003±98 
 
2,156±130 
 
3,094±127*† 
 
Calcium, mg/day 
 
758±54 
 
416±39* 
 
777±56 
 
1,755±64*† 
 
Magnesium, mg/day 
 
212±13 
 
169±11* 
 
213±14 
 
271±14*† 
 
Vitamin D, IU/day 
 
221±66 
 
149±66* 
 
208±69 
 
512±64*† 
 
Dairy, serving/day 
 
1.4±0.1 
 
0.0±0.0* 
 
1.2±0.1 
 
4.7±0.1*† 
 
Values are mean ± SEM. 
 
All significant differences were preceded by a significant condition x time 
interaction. 
 
*P<0.05 vs. Before; †P<0.05 vs. After in No Dairy condition. 
  
28 
Figure 2.1.  Participant Flow Through the Trial 
 
Participant flow through the trial.   
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Figure 2.2.  Blood Pressure 
 
Seated resting brachial systolic blood pressure (A), diastolic blood pressure (B), 
and pulse pressure (C) before and after each condition (n=49).  *P<0.05 vs. 
Before.  †P<0.05 vs. After in No Dairy condition.  Values are mean ± SEM.  
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Figure 2.3.  Time Course of Changes in Blood Pressure 
 
 
Time course of changes in casual seated brachial systolic blood pressure (A), 
diastolic blood pressure (B), and pulse pressure (C) measured weekly (n=49).  
*P<0.05 vs. week 0 within condition.  †P<0.05 vs. No Dairy. Values are mean ± 
SEM.  
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Figure 2.4.  Ambulatory Blood Pressure 
 
Ambulatory (24-hour) blood pressure before and after the High Dairy (A and C) 
and No Dairy (B and D) conditions (n=48).  *P<0.05 vs. Before.  †P<0.05 vs. 
After in No Dairy condition.  Values are mean ± SEM. 
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Chapter 3: Study 2 - Effects of Non-Fat Dairy Products Added to 
the Routine Diet on Vascular Function 
 
Abstract 
High consumption of low- and non-fat dairy products is associated with reduced 
risk of high blood pressure and central arterial stiffness.  Currently, it is not 
known if the solitary addition of non-fat dairy products to the normal routine diet is 
capable of reducing central blood pressure and/or improving cardiovascular 
function of middle-aged and older adults with elevated blood pressure.  Using a 
randomized, crossover intervention study design, forty-nine adults (44% men, 
53±2 years, 170±2 cm, 88±3 kg) with elevated BP (134±1/81±1 mmHg) 
underwent a High Dairy condition (+4 servings/day of conventional non-fat dairy 
products) and isocaloric No Dairy condition (+4 servings/day fruit products) in 
which all dairy products were removed. Both dietary conditions lasted 4 weeks 
with a 2-week washout before crossing over into the alternate condition. The 
High Dairy condition produced reductions in central systolic blood pressure (-3±1 
mmHg) and carotid-femoral pulse wave velocity (-0.5±0.1 m/sec), with a 
concomitant increase in brachial flow-mediated dilation (+1.1±0.4%) and 
cardiovagal baroreflex sensitivity (+5±1 ms/mmHg) (P <0.05 for all).  
Furthermore, changes observed in central systolic blood pressure and carotid-
femoral pulse wave velocity were highly related (r=0.55, P <0.05). On the 
contrary, brachial flow-mediated dilation was reduced after removal of all dairy 
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products in the No Dairy condition (-1.0±0.1%, P<0.05).  In conclusion, the 
solitary manipulation of conventional dairy products in the normal routine diet 
modulates levels of central blood pressure and vascular function in middle-aged 
and older adults with elevated blood pressure.  This trial was registered at 
clinicaltrials.gov as NCT01577030. 
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Introduction 
Arterial BP increases with advancing age in most industrialized countries 
resulting in a markedly high prevalence of essential hypertension, particularly in 
isolated systolic hypertension, among older adults [46].  This rise in BP is the 
major contributor to age-associated increases in risk of a number of 
cardiovascular disorders, including cerebrovascular and coronary heart disease 
[34].  The physiological mechanisms by which arterial BP increases with 
increasing age are not known.  However, structural and functional alterations of 
the large arterial wall, including stiffening of arteries, have been implicated [47].  
Increases in arterial stiffness are associated with the reduction in arterial 
endothelial vasodilatory function and arterial baroreflex sensitivity (BRS) [48, 49] 
further contributing to the elevated risks of CVD in older adults.  
To reduce the incidence of CVD, it is of paramount importance to identify 
treatments that can lower BP and restore age-related reductions in vascular 
function.  In most individuals at risk of CVD, the initial treatment approach is the 
adoption of healthy lifestyle modifications [13].  Indeed, studies that have 
evaluated lifestyle changes such as regular exercise and salt restriction have 
reported a reduction in systolic BP and an improvement in vascular function in 
middle-aged and older adults [28, 31].  We and others have reported that the 
consumption of a diet high in low- and non-fat dairy products is associated with 
the reductions in BP [15, 16, 20, 25].  Information concerning the physiological 
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mechanisms by which dairy consumption lowers arterial BP is extremely limited.  
It is plausible to hypothesize that an improvement in vascular function in general 
and de-stiffening of large arteries in particular may play an important role in 
producing the hypotensive effects of dairy products.  Indeed, previous studies 
have demonstrated reduced central arterial stiffness and improved endothelial 
function after strictly controlled dietary interventions involving supplementation 
with milk proteins [30, 32].  Currently, it is not known if the addition of 
conventional non-fat dairy products to the normal routine diet is capable of 
improving vascular function and whether such improvement in vascular function 
is associated with reductions in arterial BP.   
Accordingly, the primary aims of the present study were to determine if the 
solitary addition of conventional non-fat dairy products to the normal routine diet 
would reduce central BP and improve vascular function in middle-aged and older 
adults with elevated BP.  Central, rather than brachial, BP was used for this study 
since central BP seems to be a better predictor of hypertensive risks as well as 
the hemodynamic load imposed on the left ventricle [50].  We hypothesized that 
the addition of non-fat dairy products would reduce central systolic BP and that 
changes in BP would be accompanied by improvements in vascular function 
(e.g., reduced central arterial stiffness and increased endothelial function).  In 
order to maximally differentiate the dietary dairy intake, all dairy products were 
removed from the routine diet in the control condition.    
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Methods 
Subjects.  A total of 49 adults (44% men, 53±2 years, 170±2 cm, 88±3 kg) 
with elevated BP (134±1/81±1 mmHg) were studied.  Subjects were recruited via 
advertisements on The University of Texas at Austin website, fliers posted on the 
campus and the surrounding community, and from our database of subjects who 
participated in previous studies in the laboratory.  Inclusion criteria were: 
elevated brachial systolic BP in the seated position between 120 and 159 mmHg 
(pre-hypertension or stage-1 systolic hypertension) with a diastolic BP of less 
than 100 mmHg; no overt signs of chronic diseases on physical examination and 
medical history; normal blood chemistry; ankle-brachial index ≤0.9; non-smoker 
for previous 2 years; not lactose intolerant; dairy product consumption ≤3 
servings/day, strenuous physical activity ≤3 days/week.  Five subjects were 
taking antihypertensive medications, and medication dosages and routines were 
maintained throughout the entire study.  Prior to entrance into the study, all 
subjects underwent a 2-week “run-in period” that included 3 screening visits to 
ensure that all subjects demonstrated stable BP within the appropriate range.  
The University of Texas at Austin Institutional Review Board reviewed and 
approved the study.  All volunteers gave their written informed consent before 
participation. 
Experimental Design.  We used a controlled, randomized, crossover 
experimental design with two 4-week dietary conditions and a washout period of 
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at least 2 weeks separating dietary conditions.  The rationale for 4 weeks of 
dietary intervention was based on: a) recommendations from health care 
organizations regarding the use of non-pharmacological treatment strategies to 
improve cardiovascular risk factors; and b) the fact that vascular functions 
change very rapidly to intervention stimuli as early as 2-4 weeks [31]; therefore, 
the 4 weeks would allow a sufficient period of time for the dietary product 
stimulus to produce the hypothesized effects.  Measurements were taken at the 
beginning and end of each dietary condition at the same time of day to eliminate 
any diurnal effects and after having abstained from food, alcohol, caffeine, and 
exercise for at least 12 hours.  In premenopausal women, measurements were 
performed during the early follicular phase of the menstrual cycle.   
The 2 dietary conditions were: High Dairy condition and isocaloric No 
Dairy condition (Figure 3.1).  During the High Dairy condition, subjects added 
four daily servings of non-fat milk, non-fat fruit juice sweetened yogurt, and/or 
non-fat cheese on top of their baseline dietary dairy intake.  One serving of dairy 
was either 245 g of milk, 170 g of yogurt, or 57 g of cheese.  The research 
bionutritionist explained how much one serving of all dairy products was to each 
subject.  The subjects were free to consume the required servings at any time of 
day as a single dose or all at once.  During the No Dairy condition, all dairy 
products were removed from the diet and four daily servings of fruit juice, 
applesauce, and/or fruit cups were added to the diet.  Additional servings of fruit 
products were provided to those with regular dairy consumption at baseline to 
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counterbalance the calories lost due to removal of dairy products during the No 
Dairy condition.  Prior to the start of each dietary condition, subjects met with a 
research bionutritionist to have specific instructions about the dietary conditions 
explained to them.  After the dietary consultation, subjects received 1-week worth 
of food products and returned weekly for additional food product refills.  
Throughout the entire experimental protocol, subjects were instructed to maintain 
their normal lifestyle, aside from dietary changes prescribed by the laboratory 
research bionutritionist to reduce the overall caloric content when 4 servings of 
dairy or fruit products were added.  Research staff enrolled participants on the 
study, generated the random allocation to the treatment sequence (using a coin 
flip simple randomization procedure), and implemented the allocation sequence.  
Due to the nature of the experimental dietary conditions, it was not possible to 
blind subjects to what dietary condition they were currently in.  Additionally, there 
was no true placebo condition, as a lack of treatment provision was considered 
unethical for patients at elevated risk of cardiovascular events.  
Carotid Arterial Stiffness and BP.  After at least 10 min of rest in the 
supine position, bilateral brachial and ankle BPs, left carotid and femoral pulse 
pressure waveforms, and heart rate were simultaneously measured by an 
automated vascular testing device (Colin VP-2000, Omron Healthcare, Kyoto, 
Japan) for 30 sec at least 3 times per testing period [51].  Arterial applanation 
tonometry incorporating an array of 15 micropiezoresistive transducers recorded 
pulse pressure waveforms from the carotid and femoral arteries.  The transit time 
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was determined from the time delay between the tonometers placed on the left 
carotid and femoral arteries and was automatically measured based on the foot-
to-foot method.  The straight distance between the carotid and femoral arterial 
recording sites was measured over the surface of the body [10, 52, 53].  
Measurement distance was multiplied by 0.8 in order to adjust the distance 
closer to the real pulse pressure waveform travel distance [54].  Subsequently, 
carotid-femoral pulse wave velocity (cfPWV) was calculated as pulse pressure 
waveform travel distance divided by the transit time.  Additionally, the carotid 
pulse pressure waveforms, obtained using applanation tonometry [55], were 
recorded within an attached notebook computer and processed with dedicated 
software (WinDaq 2000, Dataq Instruments, Akron, OH).  To correct for the hold-
down pressure of applanation tonometry, carotid mean and diastolic BPs were 
calibrated to oscillometrically determined brachial mean and diastolic BPs (Colin 
VP-2000, Omron Healthcare, Kyoto, Japan), as previously described [55].   
Cardiovagal BRS.  After 10 min in the seated upright position, cardiovagal 
BRS was determined using the Valsalva maneuver, as previously described [56].  
Subjects performed at least 3 Valsalva maneuvers by forcibly exhaling against a 
closed airway.  Subjects were asked to maintain an expiratory mouth pressure 40 
mmHg for 10 seconds, while R-R interval (via electrocardiography) and beat-by-
beat BP (Pilot 9200, Colin Medical Instruments, San Antonio, TX) were 
measured continuously.  Data for cardiovagal BRS were recorded and analyzed 
by waveform browsing software (WinDaq 2000, Dataq Instruments, Akron, OH) 
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during the phase IV overshoot.  Systolic BP values were linearly regressed 
against corresponding R-R intervals from the point where R-R intervals begin to 
lengthen to the point of maximal systolic BP elevation [48, 57]. 
Brachial Flow-Mediated Dilation (FMD).  After at least 10 min of rest in the 
supine position, FMD of the brachial artery was assessed using a noninvasive, 
standardized procedure [58].  Briefly, a pneumatic BP cuff was positioned 3-5 cm 
distal to the antecubital fossa, and connected to a rapid cuff inflation device (E20 
Rapid Cuff Inflator, D.E. Hokanson, Bellevue, WA).  Brachial artery diameter and 
blood flow velocity were measured from images derived from a Doppler 
ultrasound machine equipped with a high-resolution linear array transducer 
(Philips iE33 Ultrasound System, Bothel, WA) positioned 5-10 cm proximal to the 
antecubital fossa.  After collecting 1 min each of baseline brachial artery diameter 
and blood flow velocity, the cuff was inflated to 100 mmHg above the subject’s 
brachial systolic BP for 5 min.  Blood flow velocity was recorded for 15 seconds 
after cuff deflation and then brachial artery diameter was recorded until 3 min 
past cuff deflation.  All ultrasound-derived blood flow and diameter data were 
analyzed by the same investigator using image analysis software (Brachial 
Analyzer, Medical Imaging Applications, Coralville, IA).  Brachial FMD was 
calculated using the equation: [(peak diameter – baseline diameter)/baseline 
diameter] x 100.   
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Dietary Analyses.  Subjects were given detailed instructions on how to 
keep 3-day dietary records by the research bionutritionist.  During the weekly 
visits to the laboratory to refill food products, dietary records were collected 
before and at the end of each dietary condition and analyzed using Nutritionist 
Pro software (Axxya Systems, Stafford, TX).  This software is based on the 
comprehensive food knowledge database with over 51,000 foods and 
ingredients.  Study compliance during each dietary condition was assessed by 
having each subject complete daily dietary surveys that indicated consumption of 
the food products provided, as well as any dairy products consumed as part of 
their normal diet.  
Statistical Analyses.  Power calculations were performed using nQuery 
Adviser computer software.  Sample size calculations were based on the number 
of subjects needed to detect significant changes in primary dependent variables 
from baseline levels in response to lifestyle modifications [30-33].  With 49 
subjects/group, we have greater than 80% power to detect the hypothesized 
changes.  A 2-way (condition x time) and 3-way (sex x condition x time) mixed 
model ANOVA with repeated measures was used to evaluate the effect of 
condition x time interaction by using SPSS software version 21 (IBM, Chicago, 
IL).  Where a significant interaction was found, paired-samples t-tests with a 
Bonferroni correction were conducted to determine difference between specific 
time points.  Bivariate correlations were used to determine relations between 
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dependent variables.  Statistical significance was set at P<0.05 for all analyses.  
Data are presented as mean ± SEM. 
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Results 
Subject compliance/adherence to the study protocol was 97 and 96% in 
the High Dairy and No Dairy conditions based on the daily dietary survey.  
Although no subjects blatantly consumed dairy products while in the No Dairy 
condition, a few subjects accidentally consumed dairy products (<1 serving/wk) in 
the beginning of the No Dairy intervention Additionally, a few individuals did not 
consume all servings of study food products on a daily basis.  When this 
occurred, we instructed subjects to consume the missing servings the following 
day.  Because the non-compliance here is fairly minor in nature, these subjects 
were included in the study sample.  There were no sex (gender)-related 
differences in these responses to the dietary conditions or in any of the 
responses described, as assessed by 3-way mixed model ANOVA with repeated 
measures (sex x condition x time).  Accordingly, sex was dropped from the 
analyses.  Elimination/addition of subjects with antihypertensive medications 
(n=5) did not affect the overall results.   
In the High Dairy condition, total dairy and non-fat dairy intake increased 
significantly from 1.2±0.1 and 0.3±0.1 to 4.7±0.1 and 4.0±0.1 servings/day 
(P<0.05).  Alternatively, in the No Dairy condition, in which all dairy products 
were removed from the diet, total dairy and non-fat dairy intake decreased 
significantly from 1.4±0.1 and 0.4±0.1 to 0.0±0.0 and 0.0±0.0 servings/day 
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(P<0.05).  There were no differences in total caloric intake between the two 
dietary conditions.   
  As shown in Table 3.1, there were significant reductions in supine brachial 
systolic BP, brachial pulse pressure, and ankle pulse pressure after the High 
Dairy condition (P<0.05).  Additionally, brachial pulse pressure increased 
significantly after the No Dairy condition (P<0.05).  There were no changes in 
diastolic BP after either condition.  
As depicted in Figure 3.2, carotid systolic BP decreased significantly after 
the high Dairy condition (P<0.05).  No such changes were observed after the No 
Dairy condition.  There were no changes in diastolic BP after either dietary 
condition.  Carotid pulse pressure was reduced after the High Dairy condition, but 
increased after the No Dairy condition (P<0.05 for both).  Although carotid 
augmentation index tended to be lower after the High Dairy condition, this 
reduction was not statistically significant.  Cardiovagal BRS was significantly 
higher after the High Dairy condition (P<0.05), with no change after the No Dairy 
condition.  As depicted in Figure 3.3, cfPWV was significantly reduced after the 
high dairy condition (P<0.05).  Additionally, changes observed in cfPWV after 
either dietary condition were highly related to changes in carotid systolic BP 
(r=0.55), ankle systolic BP (r=0.56), and cardiovagal BRS (r=-0.27) (P<0.05 for 
all).   
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Analysis of brachial artery characteristics before and after each dietary 
condition revealed no differences in baseline brachial artery diameter (Table 
3.1).  However, as shown in Figure 3.4, relative brachial artery FMD was 
significantly higher after the High Dairy condition, but lower after the No Dairy 
condition (P<0.05).  This trend of changes in brachial FMD was also observed 
with the absolute change in brachial artery diameter in both High Dairy and No 
Dairy conditions (0.13±0.02 to 0.16±0.02 mm and 0.13±0.01 to 0.09±0.02 mm, 
P<0.05). 
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Discussion 
The primary findings of the present randomized crossover study are as 
follows.  We found that the addition of four daily servings of conventional non-fat 
dairy products to the normal routine diet decreased central systolic BP and pulse 
pressure in middle-aged and older adults with elevated BP.  The reductions in 
central BP were related to the corresponding changes in central arterial stiffness 
and were accompanied by increased brachial FMD and cardiovagal BRS.  When 
all dairy products were removed the routine diet, central pulse pressure 
increased and brachial FMD decreased significantly.  Taken together, these 
findings indicate that the solitary manipulation of dairy products, particularly non-
fat dairy products, can modulate central BP and key vascular functions in middle-
aged and older adults with elevated BP. 
With advancing age, systolic BP increases, and diastolic BP decreases 
resulting in a widening of pulse pressure [34].  Previous studies have 
demonstrated reductions in BP after consumption of a diet high in low- and non-
fat dairy products [15-17, 20, 25].  However, these studies only measured 
peripheral BP.  In recent years, “central BP” has gathered a lot of attention as it is 
more strongly associated with vascular disease and outcome than “peripheral 
BP” measured on the brachial artery.  To the best of our knowledge, the present 
study is the first to determine the effect of dairy dietary intervention on central 
BP.  We observed that central systolic BP and pulse pressure were significantly 
47 
lower after the High Dairy condition whereas no change was observed in the No 
Dairy condition.  These results indicate that the solitary addition of conventional 
non-fat dairy products to the normal routine diet produce significant reductions 
not only in peripheral but also in central BP. 
Individuals who consume a greater number of daily servings of dairy 
products have lower central arterial stiffness [21].  Additionally, retinal damage, 
which is frequently associated with central arterial stiffening [59], is higher in 
those with lower dairy product consumption [60].  While there appears to be a 
link between dairy product consumption and vascular function, interventional 
studies to investigate these relations are very limited.  A reduction in central 
artery stiffness has been reported after a DASH diet intervention that includes 
weight loss and other dietary changes [15].  But to the best of our knowledge, 
there were no intervention studies that have examined the effects of the solitary 
addition of non-fat dairy products on vascular function.  In the present study, we 
observed significant reductions in central artery stiffness as measured by cfPWV 
after the High Dairy condition.  While not statistically significant, carotid 
augmentation index, a measure of arterial wave reflection and arterial stiffness, 
was also lower after the High Dairy condition.  Moreover, we found that changes 
in cfPWV were highly related to corresponding changes in carotid systolic BP.  
Our present findings indicate the solitary addition of conventional non-fat dairy 
products to the normal routine diet is effective in reducing arterial stiffness and 
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that the reductions in central BP may be mediated, at least in part, by reductions 
in arterial stiffness. 
Arterial baroreflex is an important short-term mechanism for regulating 
arterial BP [61] and is associated with increased risk of ventricular 
tachyarrhythmias and sudden cardiac death [62].  Decreases in the compliance 
of carotid arteries and aorta, in which the arterial baroreceptors are located, 
leads to corresponding reductions in the ability of these reflexogenic regions to 
transduce signals, resulting in decreases in cardiovagal BRS [56].  In the present 
study, we found that cardiovagal BRS increased significantly after the High Dairy 
condition.  Additionally, improvements in cardiovagal BRS were inversely related 
to changes in central arterial stiffness.  The present findings are consistent with 
previous studies that utilized other lifestyle modifications, including regular 
exercise [28, 57].  In these studies, however, increases in cardiovagal BRS were 
achieved after more than 3 months of lifestyle modifications, whereas in the 
present study, improvements were achieved as early as 4-weeks after the 
initiation of the dietary intervention.  Thus, dietary modifications involving non-fat 
dairy products, not only reduces arterial stiffness, but also improve sequela of 
arterial stiffening (i.e., cardiovagal BRS). 
Brachial FMD has been utilized as a marker of vascular endothelial 
function [63] and is strongly associated with CVD and cardiovascular event risks 
[64].  Brachial FMD increased significantly after the High Dairy condition.  
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Interestingly, when the dairy products were removed from the routine diet, 
brachial FMD decreased significantly.  Thus, the solitary manipulation of dairy 
products in their routine diet appears to modulate levels of endothelial function in 
middle-aged and older adults.  The magnitude of improvements in FMD in the 
present dietary intervention study was comparable with that observed after a 3-
month swimming exercise intervention [28].  Currently, it is not known if the effect 
of high dairy intervention is additive to the effects of other lifestyle modifications 
including exercise.  However, combined DASH diet and weight loss appear to be 
more effective at improving vascular function than DASH diet alone [15]. 
There are several strengths of the present study that can be emphasized.  
First, we kept each subject’s normal routine diet, as the baseline dietary 
conditions and only dairy and fruit consumption were experimentally manipulated 
for the High Dairy and No Dairy conditions, respectively.  We reason that such 
approach would be more generalizable to a greater number of populations who 
seek to conveniently adapt high dairy consumption in their normal diet.  
Additionally, the noninvasive measurements of vascular function performed in 
this study have been shown to be highly repeatable [10, 48, 52, 55, 57, 58], as 
well as predictive of future CVD risk [11, 64].  There are, however, several 
limitations as well.  We were unable to determine which non-fat dairy product 
was more effective in reducing BP.  Individuals in the study had the choice of 
non-fat yogurt, milk, and/or cheese, in addition to other dairy products consumed 
as part of their normal routine diet.  Additionally, we cannot determine which 
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ingredients of dairy products (milk protein, calcium, potassium, milk peptide, etc.) 
were responsible for hypotensive effects of dairy products. 
Lifestyle modifications, including dietary changes, are the first line 
approach for treating elevated BP.  The present findings indicate that simply 
adding four servings of conventional non-fat dairy products to the routine diet are 
effective in reducing central (carotid artery) systolic BP and pulse pressure in 
middle-aged and older adults.  Additionally, the addition of non-fat dairy products 
reduced central arterial stiffness and improved endothelial function.  On the 
contrary, removal of dairy products increased central pulse pressure and reduced 
endothelial function.  Unlike other lifestyle modifications, including regular 
exercise, that are difficult to achieve high compliance and adherence, dairy 
products can be easily incorporated into the daily routine to gain hypotensive as 
well as vasoprotective benefits. 
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Table 3.1.  Changes in Selected Subject Characteristics 
 
  
No Dairy 
 
High Dairy 
 
Variables  
 
Before 
 
After 
 
Before 
 
After 
 
Heart rate, bpm 
 
64±1 
 
63±1 
 
63±1 
 
64±1 
 
Supine brachial systolic BP, 
mmHg 
 
134±1 
 
135±2 
 
135±1 
 
132±2*† 
 
Supine brachial diastolic BP, 
mmHg 
 
80±1 
 
80±1 
 
80±1 
 
78±1 
 
Supine brachial pulse 
pressure, mmHg 
 
54±1 
 
56±1* 
 
55±1 
 
54±1* 
 
Ankle systolic BP, mmHg 
 
152±2 
 
152±2 
 
152±2 
 
149±2 
 
Ankle diastolic BP, mmHg 
 
80±1 
 
79±1 
 
79±1 
 
77±1 
 
Ankle pulse pressure, mmHg 
 
72±2 
 
73±2 
 
74±2 
 
71±2* 
 
Carotid augmentation index, 
% (n=43) 
 
18±3 17±3 18±3 15±3 
 
Cardiovagal BRS, ms/mmHg 
(n=44) 14±1 13±1 15±1 20±2*† 
 
Baseline brachial artery 
diameter, mm (n=47) 
 
3.8±0.1 
 
3.9±0.1 
 
3.9±0.1 
 
3.9±0.1 
 
Values are mean ± SEM (n=49 unless stated otherwise) 
 
All significant differences were preceded by a significant condition x time 
interaction. 
 
*P<0.05 vs. Before; †P<0.05 vs. After in No Dairy condition.  
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Figure 3.1.  Participant Flow Through the Trial 
 
Participant flow through the trial. 
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Figure 3.2.  Central Blood Pressure 
  
Carotid artery systolic blood pressure (A), diastolic blood pressure (B), and pulse 
pressure (C) before and after each dietary condition (n=49).  *P <0.05 vs. Before.  
†P<0.05 vs. After in No Dairy condition.  Values are mean ± SEM.  
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Figure 3.3.  Central Arterial Stiffness 
  
Carotid-femoral pulse wave velocity before and after each dietary condition 
(n=41) (A).  Relation of ∆cfPWV and ∆carotid systolic blood pressure in both 
conditions (r = .55) (B).  *P <0.05 vs. Before.  †P<0.05 vs. After in No Dairy 
condition.  Values are mean ± SEM. 
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Figure 3.4.  Brachial Flow-Mediated Dilation 
  
Brachial flow-mediated dilation before and after each dietary condition (n=47).  
*P<0.05 vs. Before.  †P<0.05 vs. After in No Dairy condition.  Values are mean ± 
SEM. 
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Chapter 4: Review of Literature 
Epidemiology of Cardiovascular Disease 
Cardiovascular disease is the number one cause of death in the US, 
accounting for nearly one-third of annual deaths [4].  This is not an emerging 
issue, as CVD has been the leading cause of death in the US for the past 80 
years [65].  Proportionally, the prevalence of CVD is higher in older adults 
compared to young or middle-aged adults, thus, the incidence of death from CVD 
is highest in older adults [34].  The reason for high prevalence of CVD in older 
adults is because the development of CVD takes years or decades, therefore, by 
nature, CVD is more prevalent in older individuals [1].  For this reason CVD is 
considered to be a disease of aging, with advancing age being its most predictive 
risk factor.  Although advances in technology and medical care have increased 
the average lifespan [66], it is reasonable to assume, based on the nature of 
CVD development and progression, that with further increases in average 
lifespan CVD will remain a top, if not the primary, cause of death.   
With aging, there are various physiological and morphological changes to 
throughout the cardiovascular system that alter the ability of the heart and 
arteries to maintain their normal function [67-71].  It is for these reasons that with 
increasing age there is a greater likelihood of CVD.  It should be noted that 
despite age being the most predictive risk factor for CVD, not all individuals 
develop CVD as they age.  Those who live a lifestyle characterized by healthy 
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eating habits, physical activity, and avoidance of tobacco products, as well as 
other risky behaviors (e.g., heavy alcohol consumption, illicit drug usage, etc.) 
tend to be at lower risk of CVD [1].  In addition to CVD, those that remain free 
from other chronic diseases associated with aging (e.g., cancer, diabetes, 
chronic obstructive pulmonary disorders, etc.) can attribute the absence of these 
diseases and CVD to their lifestyle, as well as other factors [13].  Thus, a target 
of many research investigations has been to determine ‘what the factors are?’ 
that contribute to the reduced incidence of CVD and other chronic diseases in 
these individuals.  Absence of CVD in some individuals can be attributed to 
genetic traits and other non-modifiable factors.  However, it has been suggested 
that a large part of CVD risk reduction can be attributed to modifiable lifestyle 
factors (e.g., high cholesterol, smoking status, elevated BP) [72, 73].  
Identification of modifiable lifestyle factors that reduce the risk of CVD are of 
utmost importance, as they could provide evidence on which recommendations 
can be made to individuals at risk of or already diagnosed with CVD to reduce 
further progression or risks of death associated with CVD.  Although CVD tends 
to be prevalent in later life, changes that occur through the aging process that 
lead its development begin during childhood [74].  Thus, emphasizing with even 
greater importance the need not only to investigate modifiable risk factors that 
prevent CVD, but utilize these findings to provide evidence-based 
recommendations that can be adopted earlier in life to reduce the risk of future 
disease.   
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Over the past several decades we have developed a greater 
understanding of the underlying causes of CVD.  In concert with these findings is 
the development of preventative and treatment strategies for CVD.  Thus, death 
from CVD has been greatly reduced worldwide, particularly in many high-income 
countries [75].  Unfortunately, some of these modern preventive and treatment 
strategies are expensive or unavailable to low- and middle-income countries.  
Consequently, the rates of CVD development and death are much higher in 
these countries [75].  While the adoption of healthy lifestyle modifications are 
relatively inexpensive, in some low- and middle-income countries there is less of 
a priority placed on early identification of risk factors associated with CVD [76, 
77].  Regardless of socio-economic restrictions or a subpar emphasis on early 
identification of diagnosis or risk of disease, the prevention and treatment of CVD 
through lifestyle changes are responsible for large portion of the decline in CVD 
associated deaths observed over the last 40 years [65, 78, 79].  Despite the 
enormous reductions in death, CVD remains the number one cause of death 
worldwide, even in those high-income countries that have modern prevention and 
treatment modalities available [4]. 
Blood Pressure as a Risk Factor for Cardiovascular Disease 
Throughout the developed world, the prevalence of CVD increases with 
advancing age [80].  While age is not a modifiable risk factor, there are many 
other risk factors for CVD that can be modified.  One of the most important and 
predictive of these risk factors in middle-aged and older adults is elevated BP, 
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particularly systolic BP and pulse pressure [22, 81].  The identification and 
treatment of elevated BP is largely responsible for reductions in premature death 
over the past several decades [13, 78].  Although the risk of coronary heart 
disease is greater in hypertensive than normotensive adults at any age, the 
magnitude of risk elevation associated with hypertension is much greater in older 
adults as compared with young adults [2].  Additionally, as CVD risk is closely 
associated with aging, systolic BP also tends to increases with age [82].  
Increases in BP with age are highly related to current BP.  That is those with 
elevated BP earlier in life tend to have the greatest increases in the future [5-7].  
Thus, as long-term risk of CVD in most individuals is highly related to BP, those 
age-related increases in BP may be both symptoms and predictors of CVD [2, 3].  
It is for these reasons that maintaining normal BP values through the lifespan has 
become a primary focus of aging to minimize CVD risk. 
Currently, there are more than 82 million Americans with CVD.  Among 
those with CVD 92% are hypertensive (systolic BP ≥ 140 mmHg and/or diastolic 
BP ≥ 90 mmHg or are prescribed BP lowering medications) [4].  By these 
numbers, hypertensive individuals represent more than one-third of the US 
population 20 years and older [4].  Although it appears that while high BP per se 
is not a major cause of death from CVD, accounting for only 7.5% [4], the risk of 
CVD is greater in hypertensive than normotensive adults at any age [2].  Not only 
does hypertension increase the risk of CVD, even prehypertension increases risk 
of future CVD [83, 84].  As elevated BP is one of the most important and 
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predictive risk factors for future CVD, treatment of hypertension, and even 
prehypertension [13], has become fairly aggressive, with current guidelines 
recommending the use of anti-hypertensive medications to reduce BP in most 
populations (except over the age of 65 years) with BP of 140/90 or greater [85].  
Consequently, the economic cost of CVD has risen to upwards of 300 billion 
dollars per year [4].  It is estimated that these costs will continue to rise, as 
lifespans continue to increase and lifestyles that promote CVD risk (e.g., 
sedentary lifestyle) are more common.  Clearly, from a socio-economical 
standpoint, it is of paramount importance to reduce the incidence of systolic 
hypertension, particularly isolated hypertension, in middle-aged and older adults. 
Risk Factors for Elevated Blood Pressure 
Elevated BP is highly associated with older age, but as stated previously, 
BP does not rise with age in all individuals.  Although not all risk factors for CVD 
can be modified (e.g., ethnicity, sex, and age), many that are also related to 
elevated BP can (e.g., physical inactivity, obesity, and unhealthy diet).  
Therefore, those who age with a greater number of these risk factors would also 
be more likely to have increased BP with age.  For most individuals with elevated 
BP the first line approach to reduce BP is the adoption of healthy lifestyle 
modifications [13].  However, the efficacy of lifestyle modifications can be greatly 
influenced by ethnicity, age, and sex.  For these reasons, this section will 
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examine these non-modifiable risk factors and their relations to hypertension, 
CVD, and treatment for elevated BP. 
Ethnic and Sex Differences 
While there is a greater prevalence of hypertension among older 
individuals, some ethnicities are more affected by hypertension than others.  
Non-Hispanic black adults have a higher prevalence of hypertension than do 
Hispanic and non-Hispanic white adults [86]. Treatment and identification of 
hypertension has ethnic differences, as well.  Although Hispanic adults have 
similar and sometimes lower incidence of hypertension than non-Hispanic white 
adults, they also have a lower awareness of their hypertension [86-88].  Thus, 
without being diagnosed and aware of their hypertension, Hispanic individuals 
remain untreated and at higher risk of CVD.  It is well known that non-Hispanic 
black adults have a higher prevalence of hypertension, thus they represent a 
group at higher risk of CVD.  Regardless of ethnic differences in hypertension 
prevalence, similar approaches are recommended to reduce BP [13], but some 
may be more effective than others [89].  Most notably, in non-Hispanic black 
adults, consuming a DASH eating plan has been shown to reduce BP to a 
greater extent than observed in Hispanic and non-Hispanic white adults [13, 90].   
There are also differences in hypertension prevalence between sexes, 
most notably with age [1, 89].  Although increases in prevalence of hypertension 
with age occur in both men and women, the rate of increase is different between 
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sexes [1].  In comparison to women, men tend to be at greater risk of 
hypertension and CVD, but only at younger ages [1].  It is believed that the 
menstrual hormones exert a hypotensive and vasoprotective effect on the 
vasculature of premenopausal women, reducing their risk of high BP and CVD 
[91].  Therefore, menopause-related changes in these hormones are responsible 
for the increased risk of hypertension and CVD observed in women as they age.  
It should be noted that, while BP is elevated in women after menopause, there 
are other indirect changes associated with menopause that may increase BP, as 
well, such as weight gain and salt sensitivity [92].  Overall, there are some sex-
related differences in hypertension and CVD risk, but elevations in BP occur in 
both men and women.  While men appear to be more affected earlier in age, 
there is a substantial increase in prevalence of hypertension among women after 
menopause.  Regardless of reasons for sex-related of differences in BP elevation 
with age, the treatments to reduce BP are similar between men and women. 
Lifestyle Factors that Increase Blood Pressure 
The present physiology of humans is believed to have evolved consuming 
a diet that was low in sodium.  It is estimated that late in the Paleolithic period 
dietary sodium consumption was 0.8 g/day, in contrast to the current dietary 
sodium consumption in a typical western diet that consists of 4.0 g/day [93].  
Excess dietary sodium consumption increases BP [94].  While BP tends to rise 
with age, this is not true in all countries.  For example, in undeveloped countries 
that are characterized by low sodium consumption, there is a low incidence of 
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hypertension and BP does not rise with age [94].  Although these countries tend 
to have other differences in living conditions in comparison to the developed 
world (i.e., an active lifestyle, lower chance of excess caloric intake, etc.), 
hypertension prevalence is increased even in undeveloped countries that 
consume high sodium diets [94].  Regardless of the living conditions, in most 
cases, when sodium intake is reduced BP is also reduced [31, 95], even in 
individuals with resistant hypertension [96] 
Currently, more than two-thirds of Americans are classified as overweight 
and more than one-third classified as obese.  The present prevalence of obesity 
has become a major concern in regard to CVD risk [97, 98], more so, as obesity 
rates are predicting to continue to increase.  Although the annual mortality rate 
due to CVD has decreased over the last half century, the growing prevalence of 
obesity may reverse this trend, as increased body weight is associated with 
increased BP [99-102] and central arterial stiffness [103].  Elevated systolic BP is 
by far the largest single contributor to CVD risk in adults and for most individuals 
living in industrialized societies, with advancing age comes increases in systolic 
BP [2, 3].  Thus, the impacts of an increasingly obese society will further elevate 
the rise in BP observed with aging, putting those affected at a greater likelihood 
of CVD-related risk and mortality [104].  In addition to the BP elevating effects, 
obesity is also associated with insulin resistance and risk of diabetes, both of 
which increase the risk of CVD independent of elevated BP [105].  Currently in 
the US, there are approximately 24 million adults diagnosed with type 2 diabetes 
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[106], with 79 million other Americans that are at risk or presenting preliminary 
symptoms of diabetes (e.g., insulin resistance, prediabetes, metabolic syndrome) 
[107].  This is a large number of Americans and is directly related to CVD risk as 
individuals with diabetes are at greater risk for CVD.  Additionally, there are 
various other complications associated with diabetes such as blindness, 
amputation, nerve damage, and renal failure that may all indirectly contribute to 
risk of CVD by promoting a more sedentary lifestyle [108].  A link between 
diabetes and CVD has been shown in patients with diabetes in regards to 
predictive capacity for recovery from and reoccurrence of myocardial infarction 
(MI) or other cardiovascular events.  In individuals with diabetes, the 7-year 
incidence rate of MI is equivalent to or greater than that of a non-diabetic MI 
survivor.  Thus, an individual with diabetes has the same chance of having a MI 
than an individual who has previously had a MI.  Moreover, in diabetic MI 
survivors the risk of MI reoccurrence is more than double that of non-diabetic MI 
survivors [109].  Overall, these data demonstrate that the risk of CVD and 
incidence of cardiovascular events (e.g., MI, stroke) is much greater in people 
with diabetes.  This enhanced proclivity towards CVD and cardiovascular event 
incidence emphasizes the importance of managing risk factors for CVD in people 
with diabetes, as well as the nearly 80 million other Americans that are 
considered prediabetic [110-112].   
For most adults living in industrialized societies, systolic BP, adiposity and 
BMI increase with advancing age.  As all of these increase the risk of 
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hypertension, the risk for CVD is almost inevitably increased with aging [2, 3].  
Aging cannot be avoided, but unhealthy aging that is accompanied by elevations 
in BP can be prevented with the adoption of healthy lifestyle modifications and/or 
pharmacological treatment [13].  The more elevated BP is the greater the 
increase in BP that occurs with aging [83].  Thus, a strong emphasis has been 
placed on the importance of reducing BP early and maintaining a normal BP 
(systolic BP <120 mmHg and diastolic BP <80 mmHg) to reduce the risk of future 
CVD.  To convey the seriousness of even slightly elevated BP to the general 
public, the JNC) has reclassified individuals who were once considered ‘normal’ 
(systolic BP 120-129 mmHg and/or diastolic BP 80-84 mmHg) or ‘high normal’ 
(systolic BP 130-139 mmHg and/or diastolic BP 85-89 mmHg) as 
‘prehypertensive’ (systolic BP 120-139 mmHg and/or diastolic BP 80-89 mmHg) 
[113].  While prehypertension is not a diseased state, it is thought of as a 
predecessor to diseased state as the more BP is elevated above “normal” the 
greater risk and rate of BP rise that occurs with aging [83].  Moreover, this 
reclassification places a stronger emphasis on the importance of reducing 
elevated BP early; without intervention it will most likely develop into the 
diseased state of hypertension with advancing age without intervention.   
Changes in Vascular Function with Aging and Hypertension 
Arterial BP, reported as systolic BP over diastolic BP, represents the 
pressure exerted on the walls of the arteries throughout each cardiac cycle.  
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Systolic BP corresponds to the maximum pressure, while diastolic BP is the 
minimum pressure in the arteries.  Clinical measurement of BP is typically done 
on the right arm and assesses BP in the brachial artery.  Unfortunately, 
measurement of BP in the clinical setting is subject to variability due to both 
examiner and patient error [114].  Although BP measurement in the clinical 
setting appears to be relatively simple, there are many factors that can result in 
inaccuracies including, but not limited to body position, cuff size, fasting status, 
anxiety, smoking, alcohol or caffeine consumption, distended bladder, and talking 
[114].  Therefore, guidelines have been established for the measurement of BP 
in the clinical setting, as accuracy of BP measurements is critical for prediction of 
CVD risk, as well as proper classification for BP lowering treatment [13, 115].  
Guidelines set forth by the American Heart Association call for BP to be 
measured multiple times on the right arm with the patient in the seated position 
after a 5-minute period of quiet rest [115].  The right arm should be free of 
clothing and resting at heart level, as changes in arm position, even as little as an 
inch above or below heart level can affect BP leading to inaccurate measurement 
[116].  Cuff size is of major importance in determining accurate BP.  The bladder 
of the BP cuff should encircle at least 80% of the circumference and cover two 
thirds of the length of the upper arm.  If cuff size is too small, a greater pressure 
is required to occlude the brachial artery, artificially increasing BP and potentially 
diagnosing a truly normotensive individual as hypertensive [117, 118].  Fasting 
status is major influence on BP, as consumption of a meal prior to measurement 
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can result in postprandial hypotension due to increased splanchnic blood flow 
[119].  Postprandial hypotension is of major concern in individuals who are 
hypertensive, as they tend to have the greatest decreases in BP after a meal, 
thus the amount BP is reduced after a meal can be useful in predicting future 
CVD risk [120, 121].  Additionally, those who are hypertensive, but have BP 
measured after a meal, their true BP and risk for CVD would be unknown.  On a 
related note, consumption of caffeine or alcohol is capable of transiently 
increasing BP [114].  Thus, they should be avoided prior to measurement.  There 
are many more confounding factors that influence BP that should be controlled in 
order to achieve accurate measurement of BP [122].  It is the examiner’s 
responsibility to ensure that BP measured in the clinical setting is conducted 
under repeatable conditions and conforms to American Heart Association 
guidelines.  Any deviation could influence BP measurement and result in 
inaccurate readings or underestimation of future CVD risk or cardiovascular 
events. 
There are many factors that contribute to error in BP measured in the 
clinical setting.  Fortunately, by following the appropriate guidelines for BP 
measurement, most of these factors can be reduced, however patient anxiety is 
not necessarily one of them [123].  In some individuals, BP is artificially high due 
to anxiety, this condition is referred to as white coat hypertension and can be 
determined through 24-hour ambulatory BP monitoring [124].  Although white 
coat hypertension is not a disease state, people with white coat hypertension 
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may be at greater risk of future CVD, as the regular occurrence of stressful 
situations, as might be expected in these individuals, is related to left ventricular 
hypertrophy [125].  Nevertheless, in those with white coat hypertension it is 
sometimes impossible to get an accurate reading of BP under normal clinical 
setting.  Therefore, 24-hour ambulatory BP monitoring is necessary to allow for 
measurement of BP throughout the normal daily life.  24-hour ambulatory BP 
monitoring may also be beneficial to individuals without white coat hypertension.  
Blood pressure fluctuates throughout the day, and BP measured in the clinical 
setting, as mentioned previously, is subject to error.  For these reasons, 
ambulatory BP monitoring is used in those without white coat hypertension to 
assess BP in their normal daily life.  Thus, not only can ambulatory BP 
monitoring be used to determine true BP and the risk of CVD in an individual with 
white coat hypertension, but it can also be used to determined CVD risk in those 
without white coat hypertension.  Additionally, some individuals have ‘masked’ 
hypertension.  In this condition, low BP is measured in the clinical setting, but 
their true hypertensive BP is observed during ambulatory measurement [126, 
127].  When comparing BP measured in the clinical setting to BP measured in 
the ambulatory condition, BP measured in the ambulatory condition tends to be 
slightly lower [128, 129].  Individuals whose systolic BP is 10% lower than the 
average daytime BP is considered to have a nocturnal dipping of BP, these 
individuals are hence referred to as dippers [130].  Those who are nondippers, 
do not have this decrease in BP at night and are at greater risk of CVD and left 
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ventricular hypertrophy than those that dip [38, 127, 131].  There are many 
advantages to ambulatory BP monitoring, but it should be noted that it is 
intolerable for some patients to have patients to have BP measured throughout 
the day and night.  Given these limitations, ambulatory BP monitoring is an 
accurate and predictive tool in the determination of CVD risk in normotensive and 
hypertensive individuals [132]. 
Regardless of how BP is measured at the brachial artery, whether under 
proper conditions and guidelines in the clinical setting or ambulatory condition, it 
is highly predictive of CVD risk [83].  However, brachial BP is not as predictive of 
future CVD risk, as BP measured in the central arteries (e.g., carotid arteries and 
aorta), as central BP is more representative of CVD risk [133].  Additionally, 
changes in brachial BP are not always related to changes in central BP [134].  
Brachial BP is useful for predicting CVD risk, as it is highly related to central 
arterial BP [135-137].  It is the characteristics of the central arteries that are most 
predictive of future CVD and cardiovascular events, as it is in these arteries that 
many of the deleterious structural and functional changes occur with aging and 
hypertension [133].  In fact, a major component of increased BP with age is the 
changes that occur to the stiffness or compliance of central arteries [8].  
Therefore, in most cases, the characteristics of central arteries are of greater 
importance to cardiovascular health than those of the peripheral arteries.  In 
youth, the central arteries are highly elastic and demonstrate low stiffness and 
low BP [138].  With aging, increases in stiffness of the central arteries reduce 
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their elasticity, thereby increasing BP and the future risk of CVD and 
cardiovascular events [11, 103].  A primary function of the central arteries is to 
buffer the blood ejected from the left ventricle of the heart during each cardiac 
cycle.  The buffering capacity of the central arteries is of essential for a normal 
functioning cardiovascular system, as it allows a greater stroke volume to be 
ejected while maintaining a lower pressure from the left ventricle [139].  In 
comparison to old arteries, young elastic arteries exhibit an enhanced ability to 
expand and recoil with each cardiac pulsation and relaxation [48, 56].  The 
increase in stiffness of the central arteries that occurs with aging also increases 
the workload of the heart, inducing left ventricular hypertrophy over time [140].  
As central arteries age they become more stiff and lose compliance, resulting in 
an increased velocity at which pulse pressure waveform travels through the 
arterial system [71].  The pulse pressure waveform is the sum of the forward 
(incident) and the backward (reflected) waveform [141].  With advancing age or 
hypertension in stiff arteries with decreased compliance, the velocity in which the 
pulse wave travels through the arterial tree is increased [71].  The result of this is 
a return of the reflected wave at a higher velocity [69, 71].  A primary 
consequence of increased central arterial stiffness and corresponding increased 
pulse wave velocity is that the reflected wave collides with the incident wave at 
an earlier point in the cardiac cycle [133, 139].  A collision of the reflected wave 
and incident wave, if pulse wave velocity is high enough, is an augmenting of 
systolic BP and concomitant lowering of diastolic BP, which results in an 
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increased pulse pressure [142].  Increases in systolic BP and pulse pressure, as 
well as central pulse wave velocity are positively associated with CVD and 
cardiovascular events [5, 11, 143].  It appears that increases in BP may be 
preceded by increases in central arterial stiffness [144].  Thus, analysis of 
properties related to increases in central arterial stiffness that occur with age, 
may be more important in regard to future risk of future CVD.  Additionally, 
reducing the stiffness of the large formerly elastic central arteries is a target of 
many therapeutic treatments to reduce the risk of CVD or cardiovascular events 
[28, 30-32]. 
The pathology of age-related increases in stiffness and reduction in 
elasticity of the central arteries is relatively well understood and will be explained 
later.  This portion of the review will focus on the changes in BP that occur with 
aging and that are influenced with increasing central arterial stiffness.  Blood 
pressure consists of two components: a steady-state and pulsatile component 
[145].  Both components of BP are useful in predicting CVD risk and 
cardiovascular events, but risk assessment has been shown to be different 
between components of BP in regard to age or sex [146-148].  The steady-state 
component represents the mean BP in the arteries and can be calculated from 
brachial BP using the equation: mean arterial pressure = 2/3 diastolic BP + 1/3 
systolic BP.  This formula takes into account the timing of the cardiac cycles; two-
thirds of time the heart is in diastole and to one-third it is in systole.  Thus, mean 
arterial pressure is primarily determined from diastolic BP.  In younger adults 
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diastolic BP tends to be more indicative of CVD risk, however, with aging and 
increasing central arterial stiffness, diastolic BP tends to decrease [149].  While 
mean arterial pressure does not decrease, due to relative increases in systolic 
BP with increasing age, mean arterial pressure becomes less predictive of CVD 
risk and arterial wall thickening with age [134].  It is for these reasons that the 
pulsatile component of BP has been investigated, as it is more indicative to age-
related abnormalities in central arterial stiffness than absolute BP [150].  The 
pulsatile component of BP can be calculated from brachial BP using the formula: 
pulse pressure = systolic BP – diastolic BP.  This formula represents difference 
between the maximum and minimum pressure in the arteries.  As an individual 
ages, there is an increase in the stiffness of the arteries, the velocity at which the 
pulse wave travels through the arterial tree is increased.  This results in a 
collision of the reflected and incident wave at an early point of a given cardiac 
cycle, resulting in increased systolic BP and reduced diastolic BP.  Based on this 
theory, increases in central arterial BP would increase pulse pressure [81].  
Central arterial stiffness, as measured by aortic pulse wave velocity, has been 
shown to be a strong predictor of future CVD and cardiovascular events [151-
155], but measurement of central arterial stiffness has yet to make its way into 
the clinical setting.  Thus, pulse pressure can be used as a surrogate marker to 
estimate changes in central arterial stiffness [156].  As such, pulse pressure has 
been shown to be more predictive of CVD risk in older individuals than systolic or 
diastolic BP not only in the clinical setting [35, 157], but in the ambulatory 
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condition, as well [38].  Although central arterial stiffness is not measured in the 
clinical setting, there are techniques available that have been extensively 
studied.  The gold-standard for measurement of central arterial stiffness is 
cfPWV, and is determined from the transit time of the arterial pulse from the 
carotid to the femoral artery, measured at the foot of the waveform [158].  While 
measurement of central arterial stiffness in this manner is not yet possible under 
ambulatory conditions, it is possible to estimate ambulatory central arterial 
stiffness by pulse pressure calculation or by the ambulatory arterial stiffness 
index.  The ambulatory arterial stiffness index can be calculated as one minus 
the regression slope of diastolic BP plotted against systolic BP [159].  While it is 
not a common measurement of central arterial stiffness it has shown to be highly 
related to CVD risk [160, 161].  Overall, there are several ways to assess the 
relations of central arterial stiffness and BP to CVD risk.  Although central arterial 
stiffness is not yet a measurement performed in the clinical setting, it is projected 
to make its debut in the clinical setting in the coming years. 
Central arterial stiffness increases with age, resulting in a reduced 
compliance of the central arteries [70, 71].  The compliance or elasticity of an 
artery is determined by two primary elements of the arterial wall: 1) the 
amount/proportion of the intima-media wall elastin and collagen and 2) the 
vasoconstrictor tone of the smooth muscle that surrounds the intimal layer of the 
artery [67-69].  As arteries age, structural changes to the arterial wall result in a 
reduced proportion of elastin with a comparable increase in collagen content in 
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the arterial wall [68].  Reductions in elastin are also observed at a younger age in 
animals with hypertension [162], as higher BP represents a greater strain on the 
elastin.  A common characteristic of aging is a reduced ability of the body to 
recover from a given stressor.  Theoretically, an individual with higher BP places 
a higher strain on the elastin component of the arterial wall, which results in a 
higher rate of elastin breakdown.  With aging there is a reduced ability to 
resynthesize elastin, resulting in a proportional increase in collagen [163].  
Arteries that are higher in collagen have higher stiffness, thus the pulse pressure 
waveform travels at a higher velocity throughout the arterial tree in stiff arteries, 
as compared to normal elastic arteries [164].  Collagen is stiffer than elastin; 
therefore, increases in collagen in the arterial wall reduce its ability of the arterial 
wall to buffer blood ejected from the left ventricle.  The resulting increase in BP 
also increases the workload of the heart.  Changes to the elastic components of 
the intima-media wall represent a relatively chronic adaptation that occurs slowly 
over years and is unlikely to change over a period of days or weeks [68].  Most 
lifestyle interventions that reduce central arterial stiffness or improve central 
arterial compliance tend to do so after several weeks by reducing vasomotor tone 
[28, 30-32].  Changes in vasomotor tone can occur immediately and can be 
influenced by relatively short-term (e.g., weeks) lifestyle interventions or 
pharmacological treatment [165-167].  It has been shown that participation in 
aerobic exercise in previously sedentary middle-aged and older adults reduces 
central arterial stiffness and BP [28].  Similar findings have been observed after 
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adoption of dietary changes, such as reductions in sodium intake [31] or 
consumption of milk proteins [30, 32].  It is believed that changes in arterial 
vasoconstrictor tone may account for these reductions in central arterial stiffness.  
Thus, a dietary intervention that reduces arterial vasoconstrictor tone could 
change central arterial elasticity, thereby lowering BP and overall risk of CVD.   
While increased central arterial compliance affects BP, it also likely affects 
the ability of arterial baroreceptors to modulate BP and heart rate through the 
arterial baroreflex [8].  The arterial baroreceptors are pressure-sensitive 
receptors in the walls of large elastic arteries, aortic arch and carotid sinus 
bifurcation, that stiffen and lose compliance with age [48, 56].  Changes in 
afferent signaling of the baroreceptors cause reflex-adjustments in the autonomic 
nervous system to maintain homeostatic regulation of arterial BP [168].  This 
reflex is impaired in hypertensive and older individuals with reduced large artery 
compliance [8, 169]; thus, in these individuals, there may be a reduced ability to 
increase heart rate or BP in response to a hypotensive stress.  This condition, 
orthostatic hypotension, is associated with CVD [61].  However, it has been 
demonstrated that with reductions in BP and/or increases in large artery 
compliance, there are similar improvements in BRS [28].  Similar to changes in 
central arterial stiffness or compliance, cardiovagal BRS is improved after 
exercise interventions and dietary interventions that reduce BP.  It is believed 
that changes in central arterial stiffness that occur with age, particularly in the 
carotid arteries, reduce cardiovagal BRS, thus improvements in elasticity or 
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stiffness of the central arteries would likely be accompanied by, and possibly 
related to, improvements in cardiovagal BRS. 
An additional hemodynamic factor underlying modulation of 
vasoconstrictor tone is the ability of the vascular endothelium to release 
vasoactive substances [170].  The increased bioavailability of vasoactive 
substances (i.e., nitric oxide; NO) increases central arterial compliance and has 
been shown to improve arterial endothelial function in humans [171].  Endothelial 
function is reduced with aging and hypertension [172, 173], and is highly 
predictive of risk of CVD and future cardiovascular events [174].  Briefly, the 
ability of the endothelium to release vasoactive substances that increase the 
diameter of an artery can be measured by infusing acetylcholine in an artery 
[174].  Infusion of acetylcholine stimulates endothelial nitric oxide synthase 
(eNOS) resulting in the release of NO from the vascular endothelium and 
subsequent increase in diameter of the artery.  Quantification of endothelial 
function is assessed by measuring the increase in forearm blood flow to infusion 
of acetylcholine in the brachial artery.  Additionally, ultrasound imaging of the 
brachial artery can be used as a method to quantify endothelial function by 
recording the increase in diameter of the brachial artery to a given dose of 
acetylcholine infusion.  Similar to measurements of central arterial stiffness, 
improvements in endothelial function occur after participation in an aerobic 
exercise program or the adoption of other healthy lifestyle modifications like 
dietary interventions.  While this is necessary to determine the efficacy of lifestyle 
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modifications or pharmacological intervention, acetylcholine infusion is highly 
invasive and not likely to be performed in the majority of US research institutions, 
as a medical doctor is required in most cases.  Therefore, a noninvasive 
measurement of endothelial function has been determined based on the principle 
that increases in arterial blood flow act as a shear stress that cause the 
endothelium to release vasoactive substances.   
The common, noninvasive method of measuring markers of endothelial 
function is known as FMD and is performed with ultrasound analysis of the 
brachial artery [175] or femoral artery [176].  Although the mechanisms are 
similar, for this review, the focus will be on measurement of brachial artery FMD.  
The brachial artery diastolic diameter is recorded with an ultrasound probe 
placed on the upper arm.  Then a BP cuff on the forearm is increased to a 
suprasystolic pressure distal to the ultrasound probe for 5 minutes [58].  This 
results in a period of ischemia and build up of metabolic byproducts below the BP 
cuff that cause resistance vessels below the BP cuff to dilate.  Upon cuff deflation 
a reactive hyperemic stimulus increases blood flow to the lower arm.  This 
transient increase in blood flow acts as a shear stress on the brachial artery wall.  
To normalize the shear stress vasoactive substances are released from the 
endothelium, which cause an increase in diameter of the brachial artery.  Flow-
mediated dilation is calculated as the relative increase in peak diameter after cuff 
deflation in comparison to baseline diastolic diameter using the equation: [(peak 
diameter – baseline diameter)/baseline diameter] x 100.   
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It should be noted that whether FMD truly represents NO release from the 
endothelium has recently come into question [177].  Flow-mediated dilation is 
highly related to the initial shear stimulus.  Thus, changes in FMD may be 
primarily driven by changes in other vasoactive substances in response to the 
shear stress rather than the exclusive vasodilatory action of NO [178].  This may 
represent the ability of the microvasculature or resistance arteries to dilate, 
increasing hyperemic blood flow and causing the increase in diameter of the 
larger conduit artery.  Other studies that have infused an eNOS inhibitor in the 
brachial artery have shown a minimal effect on FMD compared to a placebo 
saline infusion [178].  A recent meta-analysis estimates that although NO was 
once thought to the primary vasoactive substance released to cause FMD, likely 
it is only a minor vasodilator under this condition [179].  Regardless of whether 
NO is truly reflected from measurement of FMD, it cannot be argued that the 
ability of the artery to increase diameter in response to an increase in flow is 
highly predictive of future cardiovascular events [64].   
There is no question that endothelial dysfunction is highly related to CVD 
risk.  Many studies have shown improvements in endothelial function in response 
to acetylcholine infusion.  It has also been shown that similar changes in lifestyle 
that result in improvements in endothelial function also result in improvements in 
FMD [180, 181]. 
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Overall, there are multiple factors related to aging that contribute to 
elevated BP that occurs with advanced age.  Modulation of any one of these 
factors (e.g., endothelial function, BRS, or arterial vasoconstrictor tone) or all can 
affect the others as well as the overall rise in BP observed with aging.  Thus, it is 
difficult to determine which change in vascular function is responsible, as when 
one changes, they are all likely to change [165, 167].  Evidence of this has been 
shown through systemic infusion of an eNOS inhibitor that reduced endothelial 
function.  In this condition BP is also increased, making it nearly impossible to 
determine the effect of endothelial function on central arterial stiffness, as it is 
highly dependent on BP.  Regardless of which measurement of vascular function 
is responsible for reductions in BP observed after the adoption of healthy lifestyle 
modifications, clinical significance in terms of predicting CVD risk is high with all 
of the above measurements of vascular function. 
Treatment of Elevated Blood Pressure 
The risks of morbidity and mortality from CVD progressively rise with 
increasing BP [34].  Therefore, to reduce risk of adverse CVD-related health 
outcomes several methods of lowering BP to normal levels have been 
extensively studied [13, 14, 28, 31, 85, 89].  Additionally, identifying the beneficial 
components of a healthy lifestyle that prevent future elevations in BP have also 
been studied.  Findings from these types of studies allow for healthy lifestyle 
modifications to be identified and prescribed to individuals with elevated BP.  
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Thus, further investigation into treatments for lowering BP in hypertensive 
individuals is of great public health interest.   
Pharmacological Intervention 
In recent years, pharmacological interventions have become more 
common in the treatment and prevention of hypertension [13, 85, 89, 182-186].  
While this is not to say that pharmacological treatment is more effective than 
lifestyle modifications, risk of future cardiovascular events is reduced when 
pharmacological treatment and lifestyle modifications are combined as initial 
therapy in comparison to when lifestyle modifications are recommended as the 
sole treatment of hypertension [187].  Moreover, treatment of high BP through 
single or multiple pharmacological agents have been shown to effectively reduce 
the risk of stroke and MI [188-191].  Commonly, the first drug prescribed to lower 
BP is a thiazide-type diuretic [13, 89].  In most cases, thiazide-type diuretics are 
effective in reducing BP; however, there are many adverse side effects including 
dizziness, lightheadedness, blurred vision, loss of appetite, headache, weakness, 
and erectile dysfunction.  Other medications commonly prescribed for the 
lowering of BP are ACE inhibitors, angiotensin receptor blockers, β-blockers, and 
calcium channel blockers.  ACE inhibitors and angiotensin receptor blockers act 
through similar pathways.  Angiotensin II is a potent vasoconstrictor produced by 
the action of ACE on its substrate, angiotensin I.  Therefore, inhibition of action 
by ACE would reduce bioavailability of angiotensin II, which reduces 
vasoconstriction, as well as BP.  Angiotensin receptor blockers also alter the 
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effects of angiotensin II, but by blocking the receptor for angiotensin II thereby 
reducing BP.  Adverse side effects associated with both ACE inhibitors and 
angiotensin receptor blockers are similar to those observed with thiazide-type 
diuretics.  ACE inhibitors have been shown to be effective in improving 
cardiovagal BRS in hypertensive individuals [192, 193].  β-blockers lower BP by 
acting as an antagonist of β-adrenergic receptors.  β-receptors are found on 
cardiac, smooth muscle, kidney, and arterial tissue.  Stimulation of β1-receptors 
by epinephrine and norepinephrine increase heart rate, induce smooth muscle 
constriction, release renin from the kidneys, and promote vasoconstrictor tone in 
arteries.  All of the above increase BP, therefore, β-blockers, which act as an 
antagonist of β-adrenergic receptors, are prescribed to inhibit these responses, 
lowering BP, as well as heart rate.  Similar to β-blockers, calcium channel 
blockers reduce vasoconstriction of arteries, but do so by reducing contraction of 
the vascular smooth muscle in the artery.  In this way calcium channel blockers 
promote vasodilation and result in lowering of BP.  Although effective in lowering 
BP, many individuals who are prescribed thiazide BP lowering drugs are 
unwilling to continue due to side effects associated with pharmacological 
treatment.  Most BP medications have similar side effects, as shown above, so 
there is reluctance by many patients to begin or continue pharmacological 
treatment.  This is a major underlying issue in the successful treatment of 
hypertension in a population as a whole.  There are not many symptoms related 
to hypertension, therefore, upon administration of BP lowering drugs and onset of 
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the adverse symptoms associated with them, many decide to discontinue 
treatment.  Regardless of the adverse side effects associated with most 
pharmacological treatment of BP, it is an effective method of lowering BP in most 
individuals. 
Currently, the first line approach to reducing BP in individuals with 
elevated BP at risk for, or already having developed hypertension, is the adoption 
of healthy lifestyle modifications [13].  Adopting a healthy lifestyle that is 
successful in reducing BP reduces the risk of CVD and cardiovascular events; 
however, in many cases individuals do not attempt, or fail, to successfully 
incorporate healthy lifestyle modifications into their daily routine, and remain at 
greater risk of CVD and events.  Therefore, many individuals with elevated BP 
opt for pharmacological approach to lowering BP.  Although BP lowering drugs 
are effective in most individuals [194], there are some who do not respond to 
typical treatment guidelines and multiple drugs are needed to control BP.  
Regardless of perceived benefit of BP lowering drugs, many patients refuse to 
medicate due to their adverse side effects.  
While lower BP is related to a reduced rate of CVD and events, individuals 
who opt for pharmacological approach in absence of making healthy lifestyle 
changes may still be risk for many other diseases associated with an unhealthy 
lifestyle (e.g., diabetes, cancer, etc.).  Moreover, when healthy lifestyle 
modifications are prescribed properly and incorporated with success there is 
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almost always an equal or greater benefit for patient outcomes [13].  While many 
physicians prefer the pharmacological approach to BP reductions in their 
patients, it should be noted that the greatest reductions in BP occur with 
combined pharmacological treatment and lifestyle modifications [195].  One 
example of this is in individuals with resistant hypertension currently taking BP-
lowering drugs.  When sodium intake is reduced to very low values (~0.5 g/day) 
BP is reduced.  Therefore, regardless of the treatment plan, adopting healthy 
lifestyle modifications should be a primary component of any BP treatment 
strategy [96].  Furthermore, in most cases, pharmacological approach is 
expensive, contributing to the already large and continually growing cost of 
medical care.  Currently, medical care and hospital related expenses for CVD 
account for upwards of 300 billion dollars per year [4].  While the 
pharmacological approach to lowering BP extends the life of an individual with 
high BP, it also may increase the individuals’ medical care costs.  Those taking 
anti-hypertensive medications will likely live longer and be taking them 
throughout the remainder of their lives.  Thus, further investigation of lifestyle 
modifications that reduce BP are necessary, as they represent an inexpensive 
and effective means to reduce both BP and the economic burden of CVD and 
other chronic disease like cancer, diabetes, etc.  As stated previously, most 
individuals who attempt to make lifestyle modifications fail to do so.  Therefore, 
there is a need for the identification of more effective and realistically achievable 
84 
lifestyle modifications in order to improve patient outcomes while simultaneously 
reducing the economic cost of CVD.   
Lifestyle Modifications for the Treatment of Hypertension 
In most individuals with elevated BP, the initial treatment approach is the 
adoption of healthy lifestyle modifications, including dietary changes [13].  The 
identification of dietary changes that lower BP comes from the observation that 
dietary calcium consumption, particularly from dairy products, was lower in 
individuals with hypertension [23].  In a follow-up study it was shown that dairy 
products, fruits, and vegetables were inversely related to BP [24].  These findings 
were used to describe the DASH eating plan, which is high in fruits, vegetables, 
and low- and non-fat dairy products, but low in total fat and sodium, and has 
been shown to lower BP in individuals with elevated BP [14-19].  The DASH 
eating plan has become a mainstay of dietary modifications to reduce BP.  In one 
of the DASH interventional studies [20], subjects completed one of 3 dietary 
interventions: 1) typical western diet, 2) diet high in fruits and vegetables, and 3) 
DASH diet.  Subjects who consumed the DASH diet had the greatest reductions 
in BP.  These reductions were even greater than in those who consumed the 
fruits and vegetables diet and were attributed to the addition of low- and non-fat 
dairy products in DASH diet.  It should be noted, however, that the hypotensive 
effects of the DASH diet could not be ascribed to dairy products alone because 
other dietary changes (e.g., a reduction in total fat and saturated fat) were also 
incorporated.  
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Many interventional studies have increased daily consumption of low- and 
non-fat dairy products and shown reductions in BP [14-19], but not all studies 
found this [196-198].  Most of the studies demonstrating a hypotensive effect with 
increased daily amounts of low- and non-fat dairy products were controlled 
feeding studies or incorporated other dietary or lifestyle changes (e.g., weight 
loss, increased physical activity).  Less is known about whether the addition of 
non-fat dairy products to the normal routine diet is able to reduce BP without 
other concomitant lifestyle or dietary changes.  Additionally, the role of central 
arterial stiffness on reductions in BP in response to these types of lifestyle 
changes has not been well studied.  One study did investigate the effects on 
vascular function (cardiovagal BRS, central arterial stiffness, and brachial FMD) 
in response to a 4-month intervention of one of three conditions: 1) same lifestyle 
(control), 2) DASH eating plan, and 3) DASH eating plan plus weight loss 
(DASH+WL) [15].  While reductions in systolic and diastolic BP were greatest in 
the DASH and DASH+WL compared to control, only endpoint data for markers of 
vascular function were reported.  Brachial FMD tended to be higher, but not 
significantly different than control, central arterial stiffness, measured by cfPWV, 
was significantly lower in DASH groups compared to control [15].  The 
interpretation of these data are limited, as only endpoint data was reported and 
comparisons with control were made by combining both DASH groups (DASH 
and DASH+WL).  Furthermore, risk of CVD is increased in those with a higher 
BMI, partially due to increases in BP that are associated with weight gain.  A 
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modest weight loss substantially lowers the long-term risk of hypertension [199].  
Thus, the differences observed in this study may have been driven by reductions 
in weight from the DASH+WL group.  It has been shown that dietary 
supplementation with isolated milk proteins reduces BP while simultaneously 
improving carotid arterial compliance [30].  Additionally, individuals, who 
consume more servings of low-fat dairy products have reduced central arterial 
stiffness, as measured by cfPWV [21].  While it appears that consumption of low- 
and non-fat dairy products may in fact lower central arterial stiffness and improve 
other markers of vascular function, further study is warranted.  
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Chapter 5: Summary and Future Directions 
Summary 
Diseases of the cardiovascular system increase with advancing aging and 
are responsible for more annual deaths than any other causes [1].  One of the 
most important and predictive risk factors for CVD is elevated BP [22].  Arterial 
BP increases with advancing age in most industrialized countries resulting in a 
markedly high prevalence of essential hypertension, particularly in isolated 
systolic hypertension, among older adults [46].  This rise in BP is the major 
contributor to age-associated increases in risk of a number of cardiovascular 
disorders, including cerebrovascular and coronary heart disease [34].  Although 
the risk of coronary heart disease is greater in hypertensive than normotensive 
adults at any age, the magnitude of risk elevation associated with hypertension is 
much greater in older adults as compared with young adults [2].  The 
physiological mechanisms by which arterial BP increases with increasing age are 
not known.  However, structural and functional alterations of the large arterial 
wall, including stiffening of arteries, have been implicated [47].  
To reduce the incidence of CVD, it is of paramount importance to identify 
treatments that can lower BP and restore age-related vascular dysfunction.  In 
most individuals at risk of CVD, the initial treatment approach is the adoption of 
healthy lifestyle modifications [13].  The identification of dietary changes that 
lower BP comes from the observation that dietary calcium consumption, 
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particularly from dairy products, was lower in individuals with hypertension [23].  
In a follow-up study it was shown that dairy products, fruits, and vegetables were 
inversely related to BP [24].  These findings were used to describe the DASH 
diet, which is high in fruits, vegetables, and low- and non-fat dairy products, but 
low in total fat and sodium, and has been shown to lower BP in individuals with 
elevated BP [15, 20].  In one of the DASH diet interventional studies [20], 
reductions in BP were attributed to dairy products, but not completely as other 
dietary changes (e.g., a reduction in total fat and saturated fat) were also 
incorporated.  In support of these findings, several other interventional studies 
have shown reductions in BP after consumption of a diet high in low- and non-fat 
dairy products [15-17, 25], although some studies have not shown this [26, 27].  
Information concerning the physiological mechanisms by which dairy 
consumption lowers arterial BP is extremely limited.  Indeed, a previous study 
has demonstrated an inverse relation between dairy intake and central arterial 
stiffness [21].  Furthermore, others have demonstrated reduced central arterial 
stiffness and improved endothelial function after strictly controlled dietary 
interventions involving supplementation with milk proteins [30, 32].  
Although it was relatively established that higher dairy consumption was 
associated with lower BP, prior to this study, it was not known if the solitary 
addition of non-fat dairy products to the normal routine diet, without any other 
concomitant lifestyle or dietary changes, would be capable of reducing BP.  
Additionally, it was not known if adopting this type of dietary change was capable 
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of improving vascular function and whether potential improvements in vascular 
function would be associated with reductions in arterial BP.  In general, de-
stiffening of large arteries may play an important role in producing the 
hypotensive effects of dairy products.  Therefore, it was plausible to hypothesize 
that reductions in BP would occur and be accompanied by improvements in 
vascular function.  Accordingly, the primary purpose of this dissertation study 
was to determine if the solitary addition of conventional non-fat dairy products to 
the normal routine diet would reduce BP and improve vascular function in middle-
aged and older adults with elevated BP.  
The primary findings of the present study were as follows.  The addition of 
4 daily servings of conventional non-fat dairy products to the normal routine diet 
decreased systolic BP and pulse pressure in middle-aged and older adults with 
elevated BP.  The reduction in casual seated BP was accompanied by the similar 
reduction in ambulatory (24-hour) BP due mainly to the decrease in daytime BP.  
Additionally, we found that the addition of four daily servings of conventional non-
fat dairy products to the normal routine diet decreased central systolic BP and 
pulse pressure in middle-aged and older adults with elevated BP.  The reductions 
in central BP were related to the corresponding changes in central arterial 
stiffness and were accompanied by increased brachial FMD and cardiovagal 
BRS.  Conversely, when all dairy products were removed from the routine diet, 
pulse pressure increased significantly in central and peripheral arteries, while 
brachial FMD decreased significantly.  Taken together, these findings indicate 
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that the solitary manipulation of dairy products, particularly non-fat dairy 
products, can modulate central BP and key vascular functions in middle-aged 
and older adults with elevated BP. 
Lifestyle modifications, including dietary changes, are the first line 
approach for treating elevated BP.  The present findings indicate that simply 
adding 4 servings of conventional non-fat dairy products are effective in reducing 
both central and peripheral systolic BP and pulse pressure in middle-aged and 
older adults.  Additionally, the addition of non-fat dairy products reduced central 
arterial stiffness and improved endothelial function.  On the contrary, removal of 
dairy products increased central pulse pressure and reduced endothelial 
function.  Unlike other lifestyle modifications, including regular exercise, that are 
difficult to achieve high compliance and adherence, dairy products can be easily 
incorporated into daily routine of older adults to gain hypotensive and 
vasoprotective benefits. 
 
Future Directions 
The effects of dairy products consumption, particularly non-fat dairy, on BP 
and vascular function need further investigation.  It is clear from these data that 
the hypotensive and vasoprotective effects of dairy products are present even at 
lower levels of dairy intake (~1 serving/day), but it unclear what the minimum 
daily quantity of non-fat dairy product consumption that is required for reducing 
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BP and improving vascular function.  Therefore, it is necessary to determine the 
minimal and optimal dose of dietary dairy intake to reduce BP and improve 
vascular function.  On a related note, identification of what types of dairy 
products (e.g., milk, yogurt, cheese, etc.) are most effective in reducing BP 
remains unknown.  Identification of minimal/optimal dose and dairy product type 
that produce the greatest benefit to individuals with elevated BP is of paramount 
importance to provide more detailed recommendations on how dairy product 
consumption could reduce the impact of CVD. 
In the present study, we observed that changes in BP were related to 
central arterial stiffness.  It has been established that in addition to the reduced 
risk of high BP and CVD, diets high in low- and non-fat dairy products are also 
associated with a lower risk of diabetes [200-202].  Thus, changes observed after 
manipulation of dairy intake may also reduce risk factors for other chronic 
diseases, like diabetes.  It is possible that milk products may also affect insulin 
release and/or sensitivity, as direct mechanistic evidence of a diabetes reducing 
effect of milk products consumption has been shown in studies that found 
attenuated rise in postprandial glycemia when milk products are added to a high 
carbohydrate meal [203-205].  Insulin receptors are found on endothelial and 
vascular smooth muscle cells, and the binding of insulin at these sites results in 
insulin-mediated vasodilation achieved through a NO dependent mechanism 
[206, 207].  Therefore, it is plausible that vascular changes observed in the 
present study may be related to reductions in postprandial glycemia observed 
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after a high carbohydrate meal when milk is included.  If true, it would establish a 
mechanistic link between diabetes and CVD that could be modulated by 
increasing dairy consumption. 
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Appendix A: Abbreviations and Acronyms 
ACE = angiotensin converting enzyme 
ANOVA = analysis of variance 
BP = blood pressure 
BRS = baroreflex sensitivity  
cfPWV = carotid-femoral pulse wave velocity 
CVD = cardiovascular disease 
DASH = dietary approaches to stop hypertension 
DASH+WL = dietary approaches to stop hypertension plus weight loss 
eNOS = endothelial nitric oxide synthase 
FMD = flow-mediated dilation 
HbA1c = glycated hemoglobin 
JNC = Joint National Committee on Prevention, Detection, Evaluation, and  
Treatment of High Blood Pressure 
MI = myocardial infarction 
NO = nitric oxide 
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Appendix B: Health Research Questionnaire
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Appendix C: Daily Dietary Surveys 
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Appendix D: Three-Day Dietary Record 
 
3-Day Food Intake Record Instructions 
 
1. Record day of the week and date for everything you eat and drink for three days (two 
week days & one weekend day) prior to arriving at your appointment.   
2. Include the time, amount and type of food/beverage consumed.  Provide as much detail 
as possible, including brand names when available.  For example, instead of recording 
“cereal with milk”, record “1.5 cups Kashi GoLean cereal with 6 oz low-fat milk”.  
Instead of “1 slice wheat toast with jam”, record “1 slice Orowheat 100% whole-wheat 
toast with 1tsp Smucker’s low-sugar strawberry preserves”.  See sample food log for 
more examples.   
3. For combination foods such as chili, soup, casseroles, sandwiches, list all items in the 
food and amounts of each item.   
4. For dairy products (milk, cheese, yogurt, etc) record whether, regular (whole), lowfat 
(1%), reduced fat (2%), or non-fat (skim).   
5. Include sweeteners (sugar, honey, syrup, etc) and fats (cream, half&half, milk, etc) 
added to coffee, tea, etc; as well as spreads on breads and dressings on salads.   
6. For meats, indicate type (ground, sirloin, etc) and % lean, if known.   
 
 
 
 
-See reverse for sample food log- 
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Sample 3 Day Food Intake Day of Week: Date: 
 
 
Time 
 
Amount Brand Food/Beverage 
  8am 8 oz  Non-fat milk (in cereal) 
 12 oz  Black coffee 
 1 Tsp  Sugar in coffee 
 1.5 Cups Nature’s Path Heritage Heirloom Whole Grains Cereal 
 1 T Sun-Maid Fruit bits 
 1 medium  Cara Cara navel orange 
12pm 
1.3  Cups Homemade Chili: ½ Cup 70% lean ground beef, 1 T onion, 2 T 
garbanzo beans, 2T black beans, 2 T red sweet 
pepper 
 3 T  Grated cheddar/jack cheese, regular 
 ½ Cup  Fresh strawberries 
 ½ Cup Stoneyfield Lowfat vanilla yogurt 
 2 T  Raw almonds 
3pm 1 Cliff Chocolate Builder’s Bar 
6pm 5 oz  Grilled chicken breast, skinless 
 ¾ Cup  Slaw:  ¼ cup cabbage, ¼ grated carrots, ¼ broccoli, 1 
tsp olive oil, 1 tsp cider vinegar 
 1 piece Kirkland Signature Multigrain bread 
 2 tsp  honey 
 ½ tsp  butter 
 ¾ Cup  Grilled vegetables:  ¼ cup yellow squash, ¼ red 
pepper, ¼ cup eggplant 
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Day ___ 
  
  
3 Day Food Intake Day of Week: Date: 
 
Time 
 
Amount Brand Food / Beverage 
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Appendix E: Analysis of Blood 
After a 12-hour overnight fast, blood samples was collected by venipuncture in 
the antecubital veins of the arm.  Approximately 1 ml of blood was obtained during 
each testing visit.  Immediately following blood collection, whole blood concentrations 
of total cholesterol, HDL cholesterol, triglycerides, and glucose was measured 
enzymatically using commercially available diagnostic kits (Cholestech LDX Analyzer, 
Alere, Waltham, MA).  LDL cholesterol was estimated using the measured values of 
total cholesterol, HDL cholesterol, and triglycerides.  Whole blood HbA1c was 
measured using a commercially available HbA1c reagent kit (DCA Systems, Siemens 
Healthcare Diagnostics Inc., Tarrytown, NY).   
 
Total Cholesterol and HDL Cholesterol Measurement 
Total cholesterol and HDL cholesterol was measured by the Cholestech LDX 
Analyzer, which uses an enzymatic method.  Cholesterol esters in the sample are 
hydrolyzed by cholesterol esterase to free cholesterol and fatty acids (FFA).  Then in 
the presence of oxygen, free cholesterol is oxidized by cholesterol oxidase to cholest-
4-ene-3-one and hydrogen peroxide (H2O2).  Finally, in a reaction catalyzed by 
peroxidase (POD), the peroxide reacts with 4-aminoantipyrine and N-ethyl-N-
sulfoydroxypropyl-m-toluidine, sodium salt (TOOS) to form a purple-colored 
quinoneimine dye proportional to the total cholesterol and HDL cholesterol 
concentrations in the sample.   
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Reaction: 
1. Cholesterol esters + H20 --Cholesterol esterase--> Free cholesterol + FA 
2. Free cholesterol + O2 --Cholesterol oxidase--> Cholest-4-ene-3-one + H2O2 
3. 2 H2O2 + 4-Aminoantipyrine + TOOS --POD--> Quinoneimine dye + 4 H2O 
 
Triglyceride Measurement 
Triglycerides (TG) were measured by the Cholestech LDX Analyzer, which 
uses an enzymatic method.  Triglycerides in the sample are hydrolyzed by lipase to 
glycerol and FFA.  Glycerol is then phosphorylated by ATP to glycerol-3-phosphate 
(G-3-P) and ADP in a reaction catalyzed by glycerol kinase (GK).  In a third reaction, 
G-3-P is oxidized by glycerol phosphate oxidase (GPO) to dihydroxyacetone 
phosphate (DHAP) and H2O2.  The color reaction utilizing POD is the same as for the 
total cholesterol and HDL cholesterol. 
 
Reaction: 
1. TG + H20 --Lipase--> Glycerol + FFA 
2. Glycerol + ATP --GK--> G-3-P + ADP 
3. G-3-P --GPO-->DHAP + H2O2 
4. 2 H2O2 + 4-Aminoantipyrine + TOOS --POD--> Quinoneimine dye + 4 H2O 
 
Glucose Measurement 
Glucose was measured by the Cholestech LDX Analyzer, which uses an 
enzymatic method.  In the presence of oxygen, glucose in the sample is oxidized by 
glucose oxidase to gluconolactone and H2O2.  The color reaction utilizing POD is the 
same as for total cholesterol, HDL cholesterol, and TG. 
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Reactions: 
1. Glucose + O2 --Glucose oxidase--> o-D-gluconolactone + H2O2 
2. 2 H2O2 + 4-Aminoantipyrine + TOOS --POD--> Quinoneimine dye + 4 H2O 
 
LDL Cholesterol Estimation 
LDL cholesterol estimation was calculated by the Cholestech LDX Analyzer 
software based on the rearrangement of the algebraic formula for total cholesterol 
(total cholesterol = HDL cholesterol + LDL cholesterol + TG ✕ 0.20) to the following:  
 
LDL cholesterol = total cholesterol – HDL cholesterol – TG ✕ 0.20 
 
HbA1c Measurement 
HbA1c was measured by the DCA Vantage system, which also measures total 
hemoglobin, as % HbA1c of total hemoglobin concentration is reported.  For the 
measurement of total hemoglobin, potassium ferricyanide is used to oxidize 
hemoglobin in the sample to methemoglobin.  The methemoglobin then complexes 
with thiocyanate to form thiocyan-methemoglobin, the colored species that is 
measured.  From this reaction, the extent of color development at 531 nm is 
proportional to the concentration of total hemoglobin in the sample.  For measurement 
of HbA1c, an agglutinator containing multiple copies of the immunoreactive portion of 
HbA1c causes agglutination of latex coated with HbA1c specific mouse monoclonal 
antibody.  The agglutination reaction causes increased scattering of light, which is 
measured as an increase in absorbance at 531 nm.  HbA1c in whole blood specimens 
107 
competes for the limited number of anti-body-latex binding sites causing an inhibition 
of agglutination and decreased scattering of light.  The decreased scattering is 
measured as a decrease in absorbance at 531 nm.  The HbA1c concentration is then 
quantified using a calibration curve of absorbance versus HbA1c concentration.  The 
percent HbA1c in the sample is then calculated using the following equation: 
 
% HbA1c = 
[HbA1c] 
x 100 [Total 
hemoglobin] 
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Appendix F: Supplemental Data from Study 1 
Table F.1.  Changes in Selected Subject Characteristics and Blood Chemistry 
 
 
 
 
No Dairy Condition First (n=26) 
 
High Dairy Condition First (n=23) 
  
No Dairy 
 
High Dairy 
 
High Dairy 
 
No Dairy 
 
Variables 
 
Before 
 
After 
 
Before 
 
After 
 
Before 
 
After 
 
Before 
 
After 
 
Height, cm 
 
170±2 
 
- 
 
170±2 
 
- 
 
171±3 
 
- 
 
171±3 
 
- 
 
Body mass, kg 
 
89.5±4 
 
89.3±4 
 
90.0±4 
 
90.3±4 
 
86.1±4 
 
86.1±3 
 
85.9±3 
 
85.9±3 
 
Body mass index, kg/m2 
 
31.0±1 
 
30.9±1 
 
31.1±1 
 
31.2±1 
 
29.7±1 
 
29.7±1 
 
29.7±1 
 
29.7±1 
 
Total cholesterol, mmol/l 
 
5.40±0.2 
 
5.17±0.2 
 
5.37±0.3 
 
5.36±0.2 
 
5.14±0.2 
 
5.09±0.3 
 
5.04±0.3 
 
5.03±0.3 
 
HDL cholesterol, mmol/l 
 
1.24±0.1 
 
1.05±0.1 
 
1.18±0.1 
 
1.10±0.1 
 
1.16±0.1 
 
1.17±0.1 
 
1.27±0.1 
 
1.19±0.1 
 
LDL cholesterol, mmol/l 
 
3.60±0.2 
 
3.54±0.2 
 
3.61±0.2 
 
3.60±0.2 
 
3.30±0.2 
 
3.21±0.2 
 
3.17±0.2 
 
3.22±0.2 
 
Triglycerides, mmol/l 
 
1.21±0.1 
 
1.25±0.1 
 
1.26±0.1 
 
1.42±0.1 
 
1.49±0.2 
 
1.54±0.2 
 
1.31±0.2 
 
1.35±0.2 
 
Blood glucose, mmol/l 
 
5.36±0.1 
 
5.26±0.2 
 
5.47±0.2 
 
5.56±0.2 
 
5.20±0.1 
 
5.27±0.1 
 
5.18±0.1 
 
5.21±0.1 
 
HbA1c, % 
 
5.5±0.1 
 
5.4±0.1 
 
5.5±0.1 
 
5.5±0.1 
 
5.4±0.1 
 
5.3±0.1 
 
5.4±0.1 
 
5.3±0.1 
 
Systolic BP, mmHg 
 
134±2 
 
135±2 
 
134±2 
 
126±2 
 
135±2 
 
129±2 
 
134±2 
 
135±2 
 
Diastolic BP, mmHg 
 
80±2 
 
79±2 
 
80±2 
 
78±2 
 
81±2 
 
80±2 
 
80±2 
 
80±2 
 
Pulse pressure, mmHg 
 
54±2 
 
56±2 
 
54±2 
 
48±2 
 
54±2 
 
49±2 
 
54±2 
 
55±2 
 
Heart rate, BPM 
 
70±2 
 
67±2 
 
69±2 
 
69±2 
 
68±2 
 
69±2 
 
68±2 
 
69±2 
 
Data are presented at mean ± SEM. 
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Table F.2.  Changes in Dietary Composition 
 
 
 
 
No Dairy Condition First (n=26) 
 
High Dairy Condition First (n=23) 
 
 
 
No Dairy 
 
High Dairy 
 
High Dairy 
 
No Dairy 
 
Variables 
 
Before 
 
After 
 
Before 
 
After 
 
Before 
 
After 
 
Before 
 
After 
 
Calories, kcal/day 
 
1872±90 
 
1875±55 
 
1843±96 
 
1881±71 
 
1814±86 
 
1879±72 
 
1758±73 
 
1805±74 
 
Fat, g/day 
 
77±7 
 
60±4 
 
69±5 
 
62±5 
 
68±4 
 
58±4 
 
64±4 
 
56±4 
 
Carbohydrate, g/day 
 
204±13 
 
255±8 
 
206±14 
 
227±10 
 
200±14 
 
226±12 
 
198±13 
 
247±13 
 
Protein, g/day 
 
80±6 
 
71±4 
 
84±4 
 
96±4 
 
79±4 
 
99±5 
 
78±5 
 
66±5 
 
Alcohol, g/day 
 
6±2 
 
4±2 
 
8±3 
 
4±2 
 
13±4 
 
9±3 
 
11±3 
 
8±3 
 
Sodium, mg/day 
 
3,147±311 
 
2,671±181 
 
3,032±214 
 
2,892±204 
 
2,437±159 
 
2,566±121 
 
2,670±185 
 
2,424±165 
 
Potassium, mg/day 
 
2,051±192 
 
2,014±138 
 
2006±153 
 
2,918±109 
 
2,326±213 
 
3,291±237 
 
2,187±243 
 
1,992±141 
 
Calcium, mg/day 
 
743±72 
 
477±63 
 
738±88 
 
1,686±82 
 
822±68 
 
1,833±99 
 
775±83 
 
346±38 
 
Magnesium, mg/day 
 
200±17 
 
176±15 
 
198±3 
 
259±14 
 
229±24 
 
285±25 
 
225±20 
 
160±16 
 
Vitamin D, IU/day 
 
284±121 
 
200±122 
 
245±127 
 
540±120 
 
167±33 
 
481±28 
 
150±35 
 
92±21 
 
Data are presented at mean ± SEM. 
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Table F.3.  Specific Dairy Product Consumption 
 
 
 
 
No Dairy Condition First (n=26) 
 
High Dairy Condition First (n=23) 
  
No Dairy 
 
High Dairy 
 
High Dairy 
 
No Dairy 
 
Variables 
 
Before 
 
After 
 
Before 
 
After 
 
Before 
 
After 
 
Before 
 
After 
 
Dairy, serving/day 
 
1.3±0.2 
 
0.0±0.0 
 
0.9±0.2 
 
4.6±0.2 
 
1.4±0.2 
 
4.9±0.2 
 
1.4±0.2 
 
0.0±0.0 
 
Non-fat dairy, serving/day 
 
0.3±0.1 
 
0.0±0.0 
 
0.3±0.1 
 
4.0±0.1 
 
0.4±0.2 
 
4.0±0.1 
 
0.4±0.2 
 
0.0±0.0 
 
Full-fat dairy, serving/day 
 
0.9±0.2 
 
0.0±0.0 
 
0.5±0.1 
 
0.4±0.2 
 
0.8±0.2 
 
0.4±0.1 
 
0.6±0.1 
 
0.0±0.0 
 
Milk, serving/day 
 
0.4±0.1 
 
0.0±0.0 
 
0.3±0.1 
 
2.2±0.2 
 
0.6±0.2 
 
2.4±0.2 
 
0.5±0.1 
 
0.0±0.0 
 
Yogurt, serving/day 
 
0.2±0.1 
 
0.0±0.0 
 
0.1±0.0 
 
1.9±0.1 
 
0.2±0.1 
 
2.0±0.2 
 
0.3±0.1 
 
0.0±0.0 
 
Cheese, serving/day 
 
0.6±0.1 
 
0.0±0.0 
 
0.4±0.1 
 
0.1±0.0 
 
0.5±0.1 
 
0.1±0.0 
 
0.5±0.1 
 
0.0±0.0 
 
Other dairy, serving/day 
 
0.1±0.0 
 
0.0±0.0 
 
0.1±0.0 
 
0.4±0.1 
 
0.1±0.0 
 
0.4±0.1 
 
0.1±0.0 
 
0.0±0.0 
 
Data are presented at mean ± SEM. 
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Table F.4.  Changes in Blood Pressure in Antihypertensive Drug Users vs. Non-Users 
 
  
No Dairy 
 
High Dairy 
 
Variables 
 
Before 
 
After 
 
Before 
 
After 
 
Antihypertensive Drugs (n=5) 
    
 
Systolic BP, mmHg 
 
142±4 
 
141±6 
 
144±4 
 
136±6 
 
Diastolic BP, mmHg 
 
84±4 
 
84±5 
 
86±3 
 
84±4 
 
Pulse pressure, mmHg 
 
57±5 
 
57±3 
 
58±3 
 
51±5 
 
No Drugs (n=44) 
    
 
Systolic BP, mmHg 
 
133±1 
 
134±2 
 
134±1 
 
126±1 
 
Diastolic BP, mmHg 
 
79±1 
 
79±2 
 
80±1 
 
78±1 
 
Pulse pressure, mmHg 
 
53±1 
 
56±1 
 
54±1 
 
48±1 
 
Data are presented as mean ± SEM. 
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